The imitation switch nuclear ATPase Smarca5 (Snf2h) is one of the most conserved chromatin remodeling factors. It exists in a variety of oligosubunit complexes that move DNA with respect to the histone octamer to generate regularly spaced nucleosomal arrays. Smarca5 interacts with different accessory proteins and represents a molecular motor for DNA replication, repair, and transcription. We deleted Smarca5 at the onset of definitive hematopoiesis (Vav1-iCre) and observed that animals die during late fetal development due to anemia. Hematopoietic stem and progenitor cells accumulated but their maturation toward erythroid and myeloid lineages was inhibited. Proerythroblasts were dysplastic while basophilic erythroblasts were blocked in G2/M and depleted. Smarca5 deficiency led to increased p53 levels, its activation at two residues, one associated with DNA damage (S15 Ph 8 s ) second with CBP/p300 (K376 Ac ), and finally activation of the p53 targets. We also deleted Smarca5 in committed erythroid cells (Epor-iCre) and observed that animals were anemic postnatally. Furthermore, 4-hydroxytamoxifenmediated deletion of Smarca5 in the ex vivo cultures confirmed its requirement for erythroid cell proliferation. Thus, Smarca5 plays indispensable roles during early hematopoiesis and erythropoiesis. STEM CELLS 2017;35:1614-1623 
INTRODUCTION
Nuclear DNA is carefully packaged into chromatin, a compact nucleoprotein complex that regulates many genomic activities. Imitation switch (ISWI) proteins are Sucrose non-fermenting 2 (SNF2)-like ATPases that facilitate chromatin assembly and remodeling through their DEAD/H helicase domains located close to their N-termini. Their C-termini contain SANT and SLIDE domains that recruit a variety of bromodomain-containing factors that recognize epigenetically modified histones. ISWI proteins are integral units of several oligosubunit complexes that establish regularly spaced nucleosomes during DNA replication, cooperate with lesion-sensor proteins in DNA repair, and facilitate or inhibit transcriptional outcomes mediated by all three types of RNA polymerases (reviewed by Erdel and Rippe [1] ).
The relatively large spectrum of Smarca5 activities is enabled by structural differences in the noncatalytic subunits that provide distinct contributions to sense the state of the DNA adjacent to nucleosomes [2] . Vertebrate ISWIs are represented by two homologues: Smarca5 (Snf2h) and Smarca1 (Snf2l). While Smarca5 is expressed in stem and progenitor cells as well as in undifferentiated tumor cells, Smarca1 is expressed only at later stages suggesting that Smarca5 may be required at early stages of development when cell fate is being decided [3] . The blood system and especially erythroid cells are the most highly Smarca5expressing tissues.
Hematopoietic stem cells (HSCs) possess great potential to self-renew throughout life and to give rise to several types of multipotent progenitors (MPPs), which then differentiate along myeloid or lymphoid pathways to produce sufficient amounts of the various mature specialized blood cells. Lineage-specific transcription factors cooperate with additional factors and are often involved in epigenetic modification that is necessary to promote differentiation of self-renewing stem cells. Transcriptional regulation of early hematopoiesis has been reported to involve the SWI/SNF2-like proteins. For example, a hypomorphic mutation of the murine Brg1 ATPase results in anemia, embryonic day (E) 14.5 lethality and a blockade at the polychromatic erythroblast stage [4] . Our previous work suggested that Smarca5 is also involved in the regulation of hematopoiesis. Inhibiting its levels in human CD341 progenitors suppresses cytokine-induced erythropoiesis in vitro [5] . Conventional knockout of murine Smarca5 is lethal very early in embryonic development-long before primitive hematopoiesis is established [5] , thus preventing a determination of its role in hematopoiesis. In this article, we describe new conditional Smarca5 knock-out mouse model and use it to determine how loss of Smarca5 affects hematopoiesis. Our results show that loss of Smarca5 disrupts definitive hematopoiesis in the fetal liver (FL), causing anemia due to defects in proliferation and differentiation of both HSCs and MPPs. Smarca5 also is required for proliferation and survival of fully committed erythroid progenitors (EPs).
MATERIALS AND METHODS

Generation of Smarca5 Knock-out Mice and Cells
The Smarca5 targeting construct contained three 129Svderived murine genomic DNA fragments: (a) the 5 0 homology arm (1.5 kb PmeI-HindIII containing exon4), (b) the targeted HindIII-HindIII region (1 kb with exon5 surrounded by loxP sites (flox5; deletion of which would create a frame shift), and (c) the 3 0 homology arm (4.5 kb HindIII-HindIII containing exons 6-8) (Supporting Information Fig. S1A ). The construct was electroporated into WW6 embryonic stem cells and 2 of 12 independent clones were injected into C57Bl/6 blastocysts as described recently [6] . Detection of the targeted allele was determined by polymerase chain reaction (PCR) amplification of a 3 0 loxP-containing fragment followed by cleavage at a unique (AscI) restriction site (Supporting Information Fig.  S1B ). The floxed Smarca5 allelle can be detected by conventional PCR (Supporting Information Fig. S1C ). Germline deletion using Zp3-Cre transgene [7] produced Smarca5 1/D5 heterozygous mice that displayed reduced Smarca5 protein levels. While the Smarca5 fl 8 x5/fl 8 x5 mice were fertile and viable, the progeny of Zp3-Cre-dependent germline inactivation recapitulated the early perimplantation lethality as described previously in Smarca5 D5-9/D5-9 mice [5] . Thus, deletion of exon5 results in a null allele (Supporting Information Fig. S1E ). Methods for Supporting Information Figure S1C are provided in the Supporting Information. The Institutional Ethical Board and law on GMO approved mice handling. Mouse E12.5 FL-derived Smarca5 fl 8 x5/D5-9 Cre-Esr1 EPs (FL-EPs) or Smarca5 fl 8 x5/fl 8 x5 were cultivated [8] and treated by 1 lM4hydroxytamoxifen (4-OHT) (Tg(CAG-cre/Esr1 tax ) 5Amc ) [9] or diluent (ethanol) alone.
Cell Cycle, Clonogenic, and Apoptosis Assays
In vivo 5-Bromo-2 0 -deoxyuridine (BrdU) staining for 1 hour was analyzed by flow cytometry (see Supporting Information) on BD Canto II flow analyzer and analyzed by FlowJo software (TreeStar Inc., Ashland, OR, www.flowjo.com). Colony forming unit (CFU) assay used Methocult M3434 (StemCell Technologies, Vancouver, BC, Canada, www.stemcell.com). Approximately 4 3 10 4 FL cells were plated. Apoptosis assay used immunofluorescence (IF) of cleaved Caspase-3 and Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling (TUNEL) assays (Supporting Information).
Gene Expression
Cell staining by H&E on histology sections and cytology smears (May-Gr€ unwald-Giemsa) is described in the Supporting Information. Surface marker detection (FACS Canto II, BD Biosciences, San Jose, CA, www.bdbiosciences.com) used conjugated antibodies and published protocols [10, 11] . The microarray analysis used Affymetrix GeneChip Mouse Genome 430 2.0 Array (Affymetrix, Santa Clara, CA, www.affymetrix. com). Probes were accepted differentially expressed on False Discovery Rate (FDR) adjusted p < .01 (for more details see Supporting Information). Link to the expression data may be found in Gene Expression Omnibus database, www.ncbi.nlm. nih.gov/geo. Protocols and the antibodies used for western blotting, IF, and flow cytometry are listed in the Supporting Information. Briefly, whole protein lysates from E13.5 or E14.5 FLs were prepared in Radioimmunoprecipitation assay (RIPA) buffer supplemented with proteinase and phosphatase inhibitors. Blocking and staining was performed in Tris-buffered saline/0.1% Tween-20 with 5% milk or 3% bovine serum albumin with antibody dilutions following manufacturer's recommendations. Immunoblots were visualized by ChemiDo MP System (Bio-Rad, Hercules, CA, www.bio-rad.com).
RESULTS
Smarca5 Is Required for Definitive Hematopoiesis
We reported previously that Smarca5 null mouse embryos die shortly after implantation [5] . To investigate the role of Smarca5 in later development, we produced a conditional knock-out allele by inserting LoxP1 sites in introns 4 and 5 (Supporting Information Fig. S1A ). The Cre-recombinase-mediated removal of exon5 in the Smarca5 fl 8 x5 allele is predicted to result in a null allele due to removal of a portion of the catalytic ATPase domain, also creating a frameshift and premature stop codon. Smarca5 fl 8 x5/fl 8 x5 mice were viable, fertile, and developed normally. To study the role of Smarca5 at the onset of definitive hematopoiesis, we used a transgene that expresses iCre recombinase driven by the Vav1-promoter. Vav1 is a target of the stem cell factor receptor (c-Kit) signaling [12] and is activated in definitive HSCs starting at E10.5 [13] . Vav1-iCre transgenic mice were bred with Smarca5 1/D529 mice described previously [5] to produce the Smarca5 1/D5-9 Vav1-iCre strain. This strain was then mated with Smarca5 fl 8 x5/fl 8 x5 mice. We observed that mice with the genotype Smarca5 fl 8 x5/D5-9 Vav1-iCre are not born; other genotypes (Smarca5 fl 8 x5/1 , Smarca5 fl 8 x5/1 Vav1-iCre, and Smarca5 fl 8 x5/D529 ) were produced in the expected numbers ( Table 1) .
Analysis of embryos between days E11.5-18.5 indicated that all Smarca5 fl 8 x5/D5-9 Vav1-iCre embryos are pale-the effect is apparent at E14.5 (Supporting Information Fig. S1F ) and even more apparent at E15.5 (Fig. 1A) . Mutant embryos display significantly smaller FLs ( Fig. 1B; Supporting Information Fig. S1G ) and decreased FL cellularity (Fig. 1C) . In contrast, FL development in Smarca5 fl 8 x5/D529 mice is normal ( Fig. 1B, 1C , middle panels), suggesting that the single Smarca5 fl 8 x5 allele is not hypomorphic. By E18.5, all mutant embryos die in utero with subcutaneous swelling indicative of hemodynamic failure (Supporting Information Fig. S1H ; Table 1 ). Cytological examination of Smarca5 fl 8 x5/D5-9 Vav1-iCre FLs between E12.5 and E14.5 revealed a lack of maturing erythroid cells, whereas control FLs contained all stages of maturing erythroid cells (Supporting Information Fig. S1D , S1I). The histologic examination of E13.5 and E16.5 mutant FLs confirmed that the Smarca5 fl 8 x5/D529 Vav1-iCre FLs display disrupted structure of acinus and depletion of maturing erythroid cells in favor of immature HSCs (Fig. 1E ; Table 1 . Distribution of genotypes in utero at embryonic (E12.5-E18.5) and postnatal stages in the progeny of Smarca5 Supporting Information Fig. S1J ). Smarca5 fl 8 x5/D5-9 Vav1-iCre FLs frequently displayed dysplastic changes such as atypical and often binucleate proerythroblasts ( Fig. 1D ; Supporting Information Fig. S1I ). Erythroid hypogenesis in the mutant FLs was reflected in the peripheral blood (PB) smears at E14.5 ( Fig. 1F ) and E15.5 (Supporting Information Fig. S1K ) which showed decreased numbers of definitive (non-nucleated) erythrocytes. Instead, the PB contained large numbers of nucleated erythrocytes, indicating a defect in the embryonic-to-definitive erythropoiesis switch. HSCs at E15.5 stage control FLs expressed Smarca5, but this was not observed in the mutant FLs by immunostaining (Supporting Information Fig. S1L ). These results indicate that Smarca5 loss abrogates definitive hematopoiesis within FL, leading to anemia and E18.5 lethality.
Smarca5 Deficiency Disturbs Proliferation and Differentiation of Hematopoietic LSK and LS-K Progenitors
Because Vav1-iCre is active at the earliest stages of definitive hematopoiesis [13] , we could investigate the consequences of Smarca5 deficiency in very early HSCs. We assessed hematopoiesis of the E13.5 FL via flow cytometry using stem cell (Sca1, c-Kit) and SLAM (CD48, CD150) antigens in lineagenegative FL cells as reported previously (Supporting Information Fig. S2A ) [11, 14] . Lin-Sca11 c-Kit1 (LSK) cells are defined as Sca-1 and c-Kit-expressing cells which are depleted of lineage-positive marker expression, while the Lin-Sca1c-Kit1 (LS-K) cells are those that lack expression of Sca-1 but are positive for c-Kit and negative for lineage markers. In absolute numbers, the mutants were greatly enriched in LSK cells but not in LS-K (Supporting Information Fig. S2A; Fig.  2B ). Further analysis using SLAM antigens revealed an increase in the absolute number of MPP cells including the earliest MPP-1 (LSK 1 CD48 -CD150 1 ), myeloid-biased MPP-2 (LSK 1 CD48 1 CD150 1 ), MPP-3 (CD48 1 CD150 -) with myelolymphoid potential, as well as the Ery/Mk-biased LSKs (CD150 -CD48 -) ( Fig. 2B ). The Ery/Mk-biased LSKs represent the short repopulating stress-responsive MPPs [15] . In contrast to absolute numbers of the MPP cells, the relative numbers of MPP cells were not disturbed except for an approximate 2.5-fold increase in the myeloid-biased MPP-2 fraction ( Fig. 2A , bottom). To gain insight into the cell cycling of the accumulated MPP populations, we used in vivo BrdU labeling in E13.5 embryos. We found that the percentage of mutant E13.5 LSK cells in S-phase was increased relative to controls, whereas the percentage of these cells in G0/G1 and G2/M phases was decreased ( Fig. 2C , left). This phenomenon was observable for all analyzed MPP subpopulations (Supporting Information Fig. S2C ). This suggests that Smarca5 deletion induced proliferation of all types of the mutant LSK cells. In contrast, the mutant committed progenitors within the LS-K compartment (together with less pronounced increase in Sphase) exhibited significantly increased proportion of blocked cells in G2/M phase suggesting that upon differentiation more Smarca5-negative cells became inhibited in proliferation.
To test the proliferative potential of committed FL-derived progenitors, we used a CFU assay in methylcellulose semisolid media. While FL-derived progenitors from control E13.5 embryos formed colonies of erythroid (BFU-E, CFU-E), myeloid (CFU-GM, CFU-GG, CFU-M), or mixed (CFU-GEMM) potential, formation of these colonies by the Smarca5 fl 8 x5/D5-9 Vav1-iCre FL progenitors was severely reduced ( Fig. 2D ; Supporting Information Fig. S2D ). The effect of Smarca5 deletion was more severe within the erythroid lineage, whereas formation of myeloid colonies was only partially affected. However, the surviving myeloid colonies displayed grossly atypical Rosa26 eYFP/1 Vav1-iCre embryos scored by day 9 according to standard procedures. Similar results were obtained in at least six repeat experiments. Two-tailed Student's t test (*, p < .05; **, p < .001; ***, p < .0001; ****, p < .00001). Abbreviations: BFU, Burst-forming unit; CFU, colony forming unit; CTRL, control; LSK, Lin-Sca11 c-Kit1; LS-K, Lin-Sca1c-Kit1. morphology. The atypical morphology in the mutants included dysplastic features such as cell size and cell shape differences and unevenness within one colony as well as atypical appearance and cellularity of individual colonies. To determine whether the atypical mutant myeloid colonies underwent Cre-mediated deletion, we used a mouse strain containing a Rosa26-STOP-eYFP reporter allele. Upon deletion of a transcription terminator signal by iCre-recombinase, this strain produces eYFP fluorescence detectable by flow cytometry [16] . Indeed, as indicated by positive eYFP fluorescence, these surviving colonies expressed iCre, suggesting that the atypical morphology is a result of Smarca5 gene deletion (Supporting Information Fig. S2D ). In summary, these results indicate that the number of HSCs in Smarca5-deficient embryos is increased due to excessive cycling but their progeny, the MPPs, are blocked in their maturation.
Smarca5 Deficiency Leads to Induction of the p53 Target mRNAs in Hematopoietic Progenitors
We sought insights into the maturation defect in the mutant progenitor population by investigating their gene expression profile. We compared the levels of 39,000 transcripts in mutant (Smarca5 D5/D5-9 Vav1-iCre) and control FL-derived magnetically sorted Kit1 progenitors from E15.5 embryos by hybridization to Affymetrix GeneChip Mouse Genome 430 2.0 Array with 45,101 probes. Probes were accepted differentially expressed on FDR adjusted p < .01. Using this approach, we found 2,252 downregulated and 1,403 upregulated probes. Many of the most significant, differentially expressed gene sets among GO Biological Process categories link to response to stress, DNA damage, repair, and apoptosis, and also to hypoxia ( Fig. 3A, 3B ; Supporting Information Fig. S3A, S3D ).
According to the DAVID annotation tool, many of the genes in the KEGG p53-signaling pathway are significantly, differentially expressed in Smarca5 D5/D5-9 Vav1-iCre versus control progenitors ( Fig. 3B ). Changes in p53 pathway mRNAs are often associated with DNA damage and may result in apoptotic signaling-induced DNA fragmentation. To assess this, we used the TUNEL assay. The results showed that indeed mutant FLs exhibited a higher frequency of TUNEL-positive cells (Supporting Information Fig. S3B ). To quantify the frequency of apoptotic cells in the mutants, we determined the level of cleaved Caspase-3 in the FLs at E16.5 stage. The data show that the mutant FLs activated Caspase-3, while the control FLs showed very low frequency of Caspase-3-positive cells (Fig.  3C ). These data are consistent with upregulation of Caspase-3 mRNA level in the mutant FL progenitor cells (see Fig. 3B ).
To address whether by deleting Smarca5 at early progenitor stages, the DNA damage response (DDR) pathways became activated, we tested DDR-dependent events including the levels of p53 and its S15 Ph 8 s modification which was previously associated with DDR activation [17] . We also assessed acetylation of Lysine (K) 376 of p53 (homologous to human K382) which is mediated by p300/CBP acetylases [18] . First, we observed that the irradiated mutants expressed slightly higher level of p53 compared with controls and the level of its inhibitor Mdm2 was reciprocally decreased (Fig. 3D ). Target of p53, Ccnd2, was also increased in the mutants. Second, we also detected an increase in two p53 modifications in the mutants: S15 Ph 8 s and K376 Ac (Fig. 3D ). Additional control on the Western blots included expression of Smarca5 that again confirmed that no gene product is made from the mutant allele. Next, to further study whether the Smarca5 mutants display DNA damage, we determined gH2AX foci and p53BP1 expression using fluorescent microscopy. However, neither of these two marks were positive in the Smarca5 mutants or control FLs unlike in the positive control (irradiated wild-type thymus, Supporting Information Fig. S3E ) supporting the possibility of more complex activation of p53. We conclude that Smarca5 deficiency activated p53 at two residues, one associated with DNA damage (S15 Ph 8 s ) and another with CBP/p300 (K376 Ac ).
Smarca5 Deficiency Leads to Perturbations in Cell Cycle Progression and Inhibition of Erythroid Differentiation
The foregoing results indicate that Smarca5-deficient HSCs are able to differentiate to the MPP stage but that these progenitors are limited in their ability to mature into committed HSCs. To further investigate the causes of the block to terminal erythroid differentiation, we analyzed various stages of erythroid cell maturation within the developing FL. CD71 and Ter119 cell surface markers and flow cytometry [10] can be used to quantify cells of increasing maturation within the erythroid compartment, from the least mature cells (S0) to the terminally differentiated cells (S4 and S5) (Supporting Information Fig.  S4A ). Flow cytometry analyses showed that at E13.5, the Smarca5 fl 8 x5/D5-9 Vav1-iCre FLs exhibit a higher proportion of S0 progenitors (26% vs. 6% in controls) and their immediate progeny (S1: 7% vs. 1%; S2: 9% vs. 6%) and a reduced proportion of the more mature S3 cells (35% vs. 69% in controls) ( Fig. 4A ; left panel). This shift toward immature stages is also seen in the absolute numbers of the S0 and S1 FL erythroid populations. ( Fig. 4A ; right panel). In contrast, there is a marked reduction in the absolute numbers of the more mature S3-S5 cells. Using the Rosa26-STOP-eYFP reporter allele, we show that Vav1-iCre is expressed in several FL erythroid cell populations (Supporting Information Fig. S4B ; lower panel).
The observed shift toward immature stages in the mutant could be due to defects in cell proliferation, cell differentiation, or cell survival. To investigate cell proliferation, we used in vivo BrdU labeling and also scored the DNA content of the cells by flow cytometry after staining with 7-aminoactinomycin D (7-AAD). The E13.5 pregnant females were injected with BrdU and the FLs of the embryos were removed and analyzed for hematopoietic markers. We observed a marked decrease in the proportion of cells in S-phase in the mutant S3 population and a significant increase in cells in G2/M in the mutant S2-S5 populations. Particularly noteworthy was a marked increase in the polyploidy of G2/M cells in the mutant S3 population ( Fig. 4B ) not seen in controls (Supporting Information Fig. S4C ). Thus, Smarca5 deficiency leads to perturbations in cell cycling within the FL erythroid populations, including accumulation of cells with abnormal ploidy.
To assess the differentiation properties of the mutant cells, we used reverse transcriptase (RT)-PCR to analyze the mRNA levels of several key transcription factor genes involved in erythropoiesis. We used the Rosa26-STOP-eYFP allele to isolate eYFP-positive S0-S3 cells, which underwent Vav1-iCremediated deletion. We observed a strong reduction in Gata2 mRNA in the mutant S0 cells, and significant reductions in Gata1, Klf1, and Nfe2 mRNAs in the mutant S3 cells ( Fig. 4C ). We also assessed the expression of erythroid target genes, 1618 Smarca5 (Snf2h) in Differentiation of HSCs V C AlphaMed Press 2017
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including Epor, Alas2, and globins. Indeed, expression of definitive globin (Hba-a1 and Hbb-b1) mRNAs and the erythroidspecific Alas2 and Epor genes was significantly reduced in the mutants. Interestingly, expression of embryonic globin (Hba-x and Hbb-y) mRNAs was increased, indicating a developmental delay of erythropoiesis in the mutant (Supporting Information Fig. S4D ). In addition, no compensatory increase in Smarca5 homolog Smarca1 was observed (Supporting Information Fig.  S4D ). To determine the survival properties of the mutant cells, we used AnnexinV and propidium iodide staining by flow cytometry and found that FL cells lacking Smarca5 contain an increased proportion of apoptotic (5% in controls vs. 7% in mutants) and necrotic (3% vs. 9%) cells ( Fig. 4D ).
To assess whether the DDR pathway is involved in the shift to a more immature erythroid population in the mutant, we measured the levels of several of the DDR mRNAs identified in the microarray analysis of Kit1 cells ( Fig. 3B , in bold). We used quantitative RT-PCR to analyze mRNA levels in the . The genes in bold were also measured in Supporting Information Figure S4E . (C): Immunofluorescence for cleaved Caspase-3 in the E16.5 fetal liver (FL) (n 5 7). Caspase-3 positivity per 1 mm 2 is shown. Arrows indicate positive signals. (D): Immunoblots of FL lysates of Smarca5 fl 8 x5/D5-9 Vav1-iCre (within red rectangles) and controls either irradiated (2Gy) or nonirradiated. Irradiated NIH3T3 (15Gy) or HeLa cells were used as controls. Similar results were obtained in at least two repeat experiments. Abbreviation: FL, fetal liver. Kokavec, Zikmund, Savvulidi et al. 1619 www.StemCells.com V C AlphaMed Press 2017 eYFP1 E14.5 FL-derived S0-S3 stages. We found that all of the assayed p53 target gene mRNAs (Pmaip/Noxa, Gadd45b, Cdkn1a/p21, and Bbc3/Puma) are increased in at least one of the erythroid populations from the mutant, whereas Smarca5 mRNA and Pten mRNA are decreased in all mutant populations cells undergoing erythroid development suggesting that erythroid cells maintained activation of p53 targets upon loss of Smarca5 (Supporting Information Fig. S4E ). Thus, the induction of a DDR pathway associated with Smarca5 deficiency, observed in mutant HSC/MPP cells, occurs also in Smarca5 deficient erythroid cells.
Smarca5 Is Needed for Proliferation and Survival of EPs
Our results indicate that Vav1-iCre-mediated Smarca5 deficiency leads to perturbations in cell cycling and inhibition of maturation of HSCs at several stages of development from LSK cells to committed EPs. We next sought to determine whether Smarca5 is also required at later stages of erythroid development and whether the effects of Smarca5 deficiency on erythroid development are cell autonomous. To address the effects of Smarca5 deficiency specifically in erythroid cells, we used the Epor-iCre allele that is expressed only in fully committed EPs and their progeny [19] . All genotypes from the mating of Smarca5 1/D5-9
Epor-iCre and Smarca5 fl 8 x5/fl 8 x5 were born including the Smarca5 fl 8 x5/D5-9 Epor-iCre mice. However, closer examination of pups surviving beyond P9 indicated that the mutants were underrepresented (Supporting Information Fig. S5A ). Newborn Smarca5 fl 8 x5/D5-9 Epor-iCre pups were pale and displayed a variable degree of growth delay and failure to thrive ( Fig. 5A ). Additional study of embryos showed that indeed the E12.5-E18.5 Smarca5 fl 8 x5/D5-9 Epor-iCre embryos are anemic with reduced overall size and cellularity of the FL (Supporting Information Figs. S5B-S5D). Flow cytometric analysis of FL erythroid cells (S0-S5) showed a similar shift toward the more immature erythroid populations (S0-S1) in Smarca5 fl 8 x5/D5-9 Epor-iCre embryos ( Fig. 5B ), similar to that seen in Vav1-iCre mutant FLs. The S3-S5 populations were decreased in the mutants, although the reductions were not as large as seen in Smarca5 fl 8 x5/D5-9 Vav1-iCre FLs. This was consistent with the cytology examinations, that showed that the Smarca5 fl 8 x5/D5-9 Epor-iCre FLs were (unlike the Vav1-iCre mutants) comparably populated (to controls) by proerythroblasts and basophilic erythroblasts (Supporting Information Fig. S5E ). Colony formation assays with Smarca5 fl 8 x5/D5-9 Epor-iCre FLs showed reduced BFU-E, CFU-E, and CFU-GEMM ( Fig. 5E ), although the reductions were again not as large as seen in Smarca5 fl 8 x5/D5-9 Vav1-iCre FLs. Using the Rosa26-STOP-eYFP allele, we observed that Epor-iCre is active within the S1-S5 FL erythroid populations (Supporting Information Fig. S5H ). Consistent with the expression of Epor in the definitive erythroid cells, no delay was noted in the embryonic-to-definitive hematopoiesis switch in Smarca5 fl 8 x5/D5-9 Epor-iCre FLs (Supporting Information Fig. S5F ).
To investigate the cell proliferation and survival properties of FL erythroid cells that could account for an increase in the relative numbers of more immature populations (S0-S1) and a reduction in more mature cells (S3-S5) in Smarca5 fl 8 x5/D5-9 Epor-iCre FLs, we again used in vivo BrdU labeling and flow cytometry combined with 7-AAD, annexin V, and propidium iodide staining. We observed a marked decrease in BrdU incorporation within the S3 compartment and an increase in polyploid cells, although these defects were not as severe as in the Smarca5 fl 8 x5/D5-9 Vav1-iCre FLs ( Fig. 5C ; Supporting Information Fig. S5I ). Similarly, to Vav1-iCre mutants, there was evidence of increased apoptosis (8.5% vs. 12%) and necrosis (10% vs. 22%) in the Smarca5 fl 8 x5/D529 Epor-iCre FLs compared with controls ( Fig. 5D ).
To determine whether the observed effect of Smarca5 deficiency in the erythroid compartment is cell autonomous, we used the Cre-Esr1 allele [9] that promotes Cre-mediated inactivation upon addition of 4-OHT. We isolated FL cells from E12.5 Smarca5 fl 8 x5/D5-9 Cre-Esr1 embryos and cultured them under conditions that promote proliferation of immature EPs for several weeks [8] . Cells were cultured 24 hours before adding 4-OHT. We observed that growth of the cultures was halted quite abruptly 72 hours after addition of 4-OHT ( Fig.  5F ). These results indicate that Smarca5 is required in a cell autonomous manner for proliferation of EPs.
DISCUSSION
Smarca5 was previously shown to be an essential factor in early mammalian development [5] . In this work, we have demonstrated that it is required for maturation of definitive HSCs and for completion of erythropoiesis. We observed that mutant Smarca5 HSC/MPPs accumulate in FLs (Fig. 2B ), while the subsequent stages involving LS-K cell proliferation becomes progressively blocked at early differentiation stage ( Fig. 2C ) and CFU-forming progenitors are not able to form blood colonies ( Fig. 2D ). This leads to anemia and fetal stagelethality before birth. The phenotype is related to the Smarca5 expression, which is very high in early HSCs and proliferating progenitors and its downregulation occurs during the later stages of erythropoiesis [20] . The erythroid defect in the Smarca5 mutant mice involved a slowed onset of definitive hematopoiesis and defective proerythroblast-to-basophilic erythroblast maturation ( Fig. 4 ) marked by reduced expression of Gata1 and its target genes. These observations resemble some properties seen in erythroid cells upon deletion of the erythroid-specific transcription factor Gata1 [21] , suggesting the possibility that Smarca5 and Gata1 cooperate during erythroid differentiation. Indeed, Smarca5 and Gata1 were previously shown to physically interact in the proerythroblast/basophilic erythroblastic MEL cell line [22] . The fact that the Smarca5 mutant embros die later (E18.5) versus previously shown erythroid gene knockouts (E13.5-E15.5) [23] could be caused by later onset of the Vav1 expression, (which starts at E10.5 [12] and) which is relatively later compared with erythroid genes (e.g., Epo and Epor expression start around E8.5 and anemic FLs are observed at E11.5). The defect in erythropoiesis in Smarca5 deficient mice also partly resembles phenotypic outcome of inactivating another chromatin remodeling factor, the SWI/SNF ATPase Brg1, that resulted in anemia and embryonic lethality [4] , as well as dysregulation of the epigenetic state of the b-globin locus [24, 25] . However, the phenotype of the Brg1 mutants (compared with the Smarca5 mutants) involved more differentiated erythroid cells and did not lead to significant accumulation of early progenitors [4] . The erythroid phenotype of Smarca5 deficiency is consistent with the previously reported SMARCA5 knockdown experiment that caused an inhibition of early erythroid differentiation and led to downregulation of bglobin expression in human CD341 progenitors and K562 cells [5] . Interestingly, compared with erythropoiesis, the myelopoiesis in the Smarca5 mutant is affected less severely, consistent with SMARCA5 being a negative regulator of the myeloid transcriptional activator PU.1 [26] . As downregulation of Gata1 does not directly induce apoptosis [27] , we think that the cell death and cell cycle arrest of the Smarca5-deficient erythroblasts is rather a result of the loss of Smarca5 function in cellular pathways other than Gata1 promoted differentiation. This contention is also supported by the fact that downregulation of erythroid key regulators including Gata1, Gata2, Klf1, and Nfe2 in the FL kit1 cells and erythroid subpopulations S0-S3 from the YFP-positive fraction of Smarca5 fl 8 x5/D5-9 Vav1-iCre mutants ( Fig. 4C ) was not observed in any of the erythroid fraction of the Smarca5 fl 8 x5/D5-9 Epor-iCre mutants (Supporting Information Fig. S5J ). This conclusion is also supported by the ex vivo proliferation experiment of Smarca5deficient erythroid cells which showed that Smarca5 is required for proliferation of EPs ( Fig. 5 ).
Smarca5 deficiency affected cell cycle progression coincidently with tetraploidy and activation of a DDR. Indeed, as early as the HSC/MPP stage, the loss of Smarca5 was reflected in the increased proportion of LSK cells entering Sphase ( Fig. 2 ). Furthermore, in the next developmental step, within the LS-K cells, proliferation was markedly reduced coincidently with G2/M phase accumulation ( Fig. 2 ). Gene expression analyses at the progenitor level revealed that the most significantly affected transcriptional programs in Smarca5-deficient progenitors belonged to stressed hematopoiesis pathways including the p53 target genes ( Fig. 3 ). As expected, the p53 became activated at two residues: S15 Ph 8 s that was previously associated with DNA damage [17] and the K376 acetylation representing CBP/p300-mediated mark ( Fig  3D) . In addition, another DNA damage mark, Kap1 S824 Ph 8 s , became activated. Interestingly, the levels of Trp53 protein were increased while its inhibitor Mdm2 was reciprocally decreased in the mutants. However, we have not confirmed the Atm/Atr pathway activation of Chk1/Chk2 (Supporting Information Fig. S3C ) upon Smarca5 deficiency. We conclude that Smarca5 deficiency activated two activating modifications of p53. However, our data also show that gH2AX staining was not enriched in the mutants supporting possibility of more complex mechanism upstream the p53 activation.
Stressed hematopoiesis induced by genotoxic agents in HSC is often coupled with Gadd45a-mediated activation of MPPs followed by erythromegakaryocytic and myelolymphoid differentiation [28] . However, this wave of coordinated proliferation and differentiation does not occur upon Smarca5 deficiency and instead the mutant cells are blocked from proliferation at the tetraploid state, which prevents further completion of cell differentiation. In addition, a significant proportion of the mutant cells underwent the p53-mediated apoptosis ( Fig. 3) , which further aggravated the anemic phenotype. Polyploidy was also previously shown to increase tolerance to mitotic errors [29] and may result in appearance of binucleate-like cells [30] that were also readily observable in the mutant FLs. Activation of p53 and its program including induction of p21 as a consequence of polyploidy has been observed experimentally upon addition of microtubule assembly inhibitors [31] . In addition, another activator of p21 was overrepresented in the mutants such as Kap1 S824 Ph 8 s (Fig. 3D ). Interestingly, p21 could be also activated by hypoxia via Hypoxia-inducible factor 1 (HIF-1) [32] supporting the possibility that both p53 and p21 activation could be augmented by severe hypoxia [33] as also documented by activation of the HIF-1 mRNA targets (Supporting Information Fig. S3D ). Smarca5 deficiency thus disrupted the proliferation of HSCs differentiating into erythroid lineage, affecting its development, and causing severe anemia. Tp53 activation appears to be a mediator of the proliferation blockade and apoptosis in the Smarca5 mutants.
CONCLUSION
Smarca5 deficiency suppressed hematopoietic development and caused erythroid dysplasia and anemia coincident with activation of the p53 and its program. If Smarca5 is not available, the cell cycle progression becomes progressively inhibited at the MPP level at G2/M phase leading to erythroid defect and severe anemia.
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T he production of mature T and B cells is a multistep process of differentiation from a multipotent progenitor that requires a coordinated regulation of gene expression, replication, DNA rearrangement, and repair. Progenitors of T cells migrate from the bone marrow (BM) into the thymus where they respond to a new environment by initiating a transcriptional program of T cell specification while proliferating extensively (1) . During this process, CD4 2 CD8 2 double-negative (DN) CD44 + positive early T lineage precursors (immature DN1) permanently silence the group of progenitor-related regulatory genes leading to the gradual upregulation of CD25 and the downregulation of c-Kit surface markers and resulting in the commitment completion at the end of the DN2 stage (CD44 + CD25 + c-Kit int ) (2) . Thymocytes at the subsequent DN3 stage (CD44 2 CD25 + ) cease from cycling and, importantly, undergo a random rearrangement of gene segments at the TCRb locus and commence the expression of components related to the b-selection program. Upon the successful rearrangement that yields functional pre-TCR complexes, thymocytes proliferate rapidly, become rescued from the p53regulated cell cycle arrest and apoptosis (3), and then are allowed to progress into the DN4 stage (CD44 2 CD25 2 ). This transient population hence upregulates the expression of CD4 and CD8 to become double-positive (DP) cells and initiates TCRa locus rearrangement. DP cells with productive TCRab are positively and negatively selected so that only those with "proven" TCR can undergo differentiation into CD4 or CD8 single-positive (SP) cells (4). Eukaryotic cells evolved numerous epigenetic regulatory mechanisms of gene expression, DNA replication, and repair to accomplish the T cell development. During early T cell differentiation, NURD and SWI/SNF chromatin-remodeling complexes were shown to play important roles in both activating as well as silencing the gene transcription (5, 6) . The SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5 (Smarca5) represents a widely expressed and conserved chromatin-remodeling factor required for the early development in mouse and lower organisms (7) . Smarca5 is an ORCIDs: 0000-0003-2452-3749 (T.Z.); 0000-0003-0267-4570 (J.K.); 0000-0002-5329-1812 (T.T.); 0000-0002-6479-6592 (H.P.); 0000-0003-0315-5668 (S.V.); 0000-0001-7236-6894 (T.S.).
Received for publication January 2, 2019. Accepted for publication April 15, 2019. ATPase from the ISWI subfamily that functions as a molecular motor for nuclear complexes that assemble and slide basic chromatin subunits, nucleosomes. Smarca5-containing complexes have diverse nuclear functions: guiding the transcription of ribosomal (in NoRC and B-WICH complexes) and some coding genes (within the ACF or RSF complexes), participating in regularly spacing the nucleosomal array before and after DNA replication, facilitating the recruitment of DNA repair machinery (CHRAC and WICH complexes), and finally, orchestrating higher-order chromatin structure formation of centromeres and chromosomes (RSF) (8) . Although several members of SWI/SNF and CHD family have had their roles established in T cell development through studies involving gene inactivation mouse models, such a role for the ISWI subfamily has not been determined yet.
Currently, there is only a limited knowledge of how Smarca5, which is highly expressed in lymphocytes (9) , participates in lymphopoiesis. We previously showed that deletion of the Smarca5 gene resulted not only in the depletion of myeloerythroid precursors but also affected the earliest development of lymphoid progenitors in the mouse fetal liver (10) . Additionally, Smarca5 was implicated in the V(D)J cleavage of the polynucleosomal substrate in a cell-free system (11) . Another report implicated that Smarca5 in the ACF complex represses the IL2-Ra gene (CD25) via chromatin organizer Satb1 (12) . Lastly, Smarca5 regulates the expression of key ILs (IL-2, IL-3, and IL-5) in murine EL4 T cell lymphoma (13) . Although the role of Smarca5 in lymphopoiesis was previously suggested, the knockout models of Smarca5-interacting partners revealed no alterations in lymphoid development, including the deletion of Acf1/Baz1a (ACF and CHRAC complexes) (14, 15) or Tip5/Baz2a (NoRC) (15) genes in mice. Interestingly, it has been shown in vitro that Smarca5 can also remodel nucleosomes alone without being part of the complexes (16) . As several of Smarca5-interacting partners are dispensable, studying the requirement of a catalytic subunit of the ISWI complexes by targeting experimentally Smarca5 during lymphoid development may represent a successful strategy to reveal its function in lymphopoiesis.
We, in this study, focused on deciphering the role of Smarca5 in thymocyte development and studied the molecular consequences of conditional Smarca5 deficiency in mice. Our work suggests that Smarca5 controls early T cell development by guiding early differentiation-coupled transcriptional programs at the DN3 stage and its deficiency results in thymocyte proliferation and survival defects through the activation of the DNA damage response. 
Materials and Methods
Flow cytometry
A single cell suspension from thymi and spleens of 4-6-wk-old mice was obtained using a Dounce homogenizer. Cells were first preincubated for 10 min on ice with Fc receptor-blocking anti-CD16/32 (clone 93) Ab in PBS-1% biotin-free BSA solution and then stained for 20 min with specific primary Abs. Biotinylated primary Abs were revealed with streptavidinconjugated fluorescent dyes (SAv-PE/Cy7, SAv-APC, and SAv-APC/Cy7). Labeled cells were analyzed on BD FACSCanto II (BD Biosciences) or CytoFLEX (Beckman Coulter) flow cytometers, and data analysis was performed using FlowJo software. The clones of mAbs were as follows: anti-CCR6 (29-2L17), anti-CD3ε (145-2C11), anti-CD4 (GK1.5), anti-CD5 (53-7.3), anti-CD8 (53-6.7), anti-CD11c (N418), anti-CD24 (M1/69), anti-CD25 (PC61), anti-CD27 (LG.3A10), anti-CD28 (E18), anti-CD44 (IM7), anti-CD45.1 (A20), anti-CD45.2 (104), anti-CD71 (RI7217), anti-CD73 (TY/11.8), anti-CD117 (c-Kit, 2B8), anti-B220 (RA3-6B2), anti-CD11b (Mac1, M1/70), anti-gd T cell (GL3), hamster IgG-PE/Cy7 (HTK888), anti-Ly6G/Ly6C (GR1, RB6-8C5), anti-Nk1.1 (PK136), anti-TCRb (H57-597), anti-TCRb(Va2) (B20.1), and Ter-119 (all from BioLegend). Splenocytes were analyzed as previously described (18) .
BM transplantation
For BM reconstitution experiments, 1 3 10 7 BM cells from adult (8-wkold) control C57BL/6J Ly5.1 (CD45.1) mice and S5 fl/fl hCD2iCre Ly5.2 (CD45.2) donors were reciprocally transplanted into lethally irradiated (7.5Gy) adult (8 wk) S5 fl/fl hCD2iCre Ly5.2 and C57BL/6J Ly5.1 control recipients, respectively. After 1 mo posttransplantation, thymi were tested for the presence of donor-derived cells using flow cytometric analysis. The Ab panel included CD45.1, CD45.2, CD44, CD25, CD4, lineage mixture (CD8, B220, Mac-1, Gr-1, Nk1.1, CD11c, and Ter119) and CD45.1, CD45.2, CD4, CD5, CD8, and lineage mixture (B220, Mac-1, Gr-1, Nk1.1, CD11c, and Ter119) for thymus.
BrdU labeling
Smarca5 conditional knockout mice and their age-and gender-matched respective controls were i.p. injected with 1 mg of BrdU in 100 ml PBS. After 3 h, the thymocytes were isolated and Ab-stained for flow cytometry analysis or cell sorting. BrdU Ag recovery and its detection by fluorescently labeled Ab were performed using the APC BrdU Flow Kit (BD Biosciences).
OP9/N-DLL1 stromal cell cultures
FACS-sorted DN3 thymocytes (small CD4 2 CD8 2 CD25 + ) and Lin 2 Sca1 + Kit + (LSK) BM cells were cocultured with OP9 stromal cells expressing the Delta-like ligand (OP9/N-DLL1) in the presence of 1 ng/ml mIL-7 (407-ML-005) and 5 ng/ml hrFLT3 ligand (308-FK-005; PeproTech) as previously described (19) . In BM cell cocultures, the concentration of IL-7 was lowered to 0.1 ng/ml from day 12 to allow differentiation. For CFSE labeling, 3 3 10 4 DN3 cells were stained with 2.5 mM CFSE following the manufacturer's guidelines (CellTrace CFSE Cell Proliferation Kit; Invitrogen) and plated onto OP9 stromal cultures. Their proliferation and survival were analyzed by flow cytometry at 2, 4, 6, and 8 d of cocultures. OP9/N-DLL1 cells were kindly provided by Hiroshi Kawamoto (Kyoto University).
Histopathology and the detection of apoptotic cells in thymic sections
Thymi and spleens were fixed in 4% buffered formaldehyde for 48 h, transferred in 70% ethanol, and paraffin embedded. Sections were obtained at 3 mm thickness and stained in H&E and Giemsa. Cleaved Caspase-3 was detected by immunohistochemistry using a 1:1000 dilution of Ab (ab52293; Abcam) and visualized on a Zeiss Axio Scan.Z1. Casp3-positive cells were quantified using the Zen Blue Edition software (ZEISS).
RNA sequencing analysis
CD4 + CD8 + (B220 2 Gr-1 2 Nk1.1 2 CD11c 2 CD11b 2 ) thymocytes were sorted by FACS, and the total RNA was isolated using TRIzol Reagent (Invitrogen). DP cells pooled from 25 to 37 S5 fl/fl hCD2iCre thymi (each pool of 3 3 10 6 DP cells), 6 S5 fl/fl hCD2iCre Trp53 2/2 thymi (∼2.5 3 10 6 DP cells/pool), and single nonpooled control thymi provided sufficient amounts of RNA for RNA sequencing analysis. Strand-specific cDNA libraries were prepared from a minimum of 1.7 mg of each DNase-treated (AM1906; Ambion DNA-Free Kit) RNA sample using the TruSeq Stranded mRNA LT Kit (Illumina). The RNA libraries were sequenced on an Illumina HiSeq 2500 instrument in Rapid Run mode with paired-end 100-bp sequencing length. Reads were mapped and aligned to mouse reference genome assembly GRCm38.p6, and transcripts were annotated and counted with Ensembl Release 94 (October 2018) using a HISAT2 aligner (20) . The two RNA-seq technical replicates for each sample were combined. Differential expression analysis of RNA-seq data were performed in R Studio (21) using package DEseq2, which uses a median of ratios normalization method that accounts for sequencing depth as well as RNA composition (22) . Volcano plots were drawn using the ggplot2 (23) package in R suite. Expression levels (transcripts per kb million) for Ensembl 94 genes were calculated in R using gene lengths retrieved by EDASeq package (24) and in-house scripts. The shrinkage of log 2 fold change values (log 2 FC) was estimated using DESeq2 lfcShrink function using the adaptive t prior shrinkage estimator "apeglm" (25) . The RNA-seq data are publicly available at the ArrayExpress database under accession number E-MTAB-7758 (https://www.ebi.ac.uk/arrayexpress/ experiments/E-MTAB-7758/). 
Quantitative PCR
Immunoblotting
Freshly isolated thymocytes were collected by centrifugation and resuspended in PBS with inhibitors of phosphatases (PhosSTOP; Roche) and proteases (cOmplete ULTRA; Roche). The cell suspension was then diluted 1:1 by adding a solution of 50 mM Tris-Cl (pH = 8) and 2% NaDodSO 4 (SDS) and incubated for 30 min at 97˚C. Protein concentration was determined by bicinchoninic acid assay (no. 23228; Pierce Biotechnology). Proteins were then resolved on SDS gradient 4-15% polyacrylamide gels (Mini-PROTEAN TGX Stain-Free Gels; Bio-Rad Laboratories) and wet blotted (1 h at 100 V) onto PVDF membranes (no. 162-0177; Bio-Rad Laboratories). PVDF membranes were blocked for 1 h in 5% nonfat milk in TBS/0.1%Tween-20 (TBST) and incubated overnight at 4˚C in 3%BSA/ TBST 0.1% sodium azide with the following Abs: Smarca5 (1:1000, no. A301-017A-1; Bethyl Laboratories) and histone H3 (1:1000, no. ab791; Abcam). Membranes were 3 3 5 min washed in TBST buffer and incubated with peroxidase-conjugated F(ab9)2 Ab fragment, either donkey antirabbit or donkey anti-mouse (1:10,000; Jackson ImmunoResearch), in 5% nonfat milk in TBST for 1 h. Membranes were 3 3 5 min washed in TBST, and the protein signal was visualized by Pierce SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific) and detected with the ChemiDoc Imaging System (Bio-Rad Laboratories).
Results
Smarca5 deficiency disrupts thymocyte development
To delineate specific roles of Smarca5 in vivo, we previously created the Smarca5 fl allele containing two loxP1 sites surrounding exon5, the deletion of which results in removing the portion of evolutionarily conserved helicase domain and introducing a frame-shift mutation (10, 17) ( Fig. 1A) . To execute the T cell-specific deletion of the Smarca5 gene, we crossed Smarca5 fl/fl mice with hCD2iCre transgenic mice, in which the hCD2 promoter and locus control region drive the expression of the iCre recombinase (26) . Use of the hCD2-iCre transgene to study thymocyte development was chosen as this model alone caused no defect in thymus development (27) as well as the cellularity and subset composition of the major lymphoid organs (including thymus, spleen, and lymph nodes) did not differ between hCD2-iCre-expressing mice and wild-type (wt) (28) . We initially evaluated the onset of the Smarca5 fl gene deletion by PCR. Genomic DNA was prepared from FACS-sorted CD4/CD8 DN thymocyte subpopulations of Smarca5 +/fl hCD2iCre mice and three primer sets amplifying wt, Smarca5-floxed (S5 fl ), and recombined-floxed (S5 del ) allele were used. Consistent with previous reports that used the hCD2iCre transgene (26), we observed Cre-mediated recombination of loxP1 sites as early as the DN1 stage in which the recombined S5 del allele was detectable ( Fig. 1B) . However, the deletion of the S5 fl allele at DN1 was only partial, whereas its complete deletion was observed at the DN3 stage. Western blot analysis of the whole thymic cellular extracts from S5 fl/fl hCD2iCre mice confirmed a high efficiency of recombination as we observed a marked reduction of Smarca5 protein levels (Fig. 1C) .
S5 fl/fl hCD2iCre pups were born healthy and at normal Mendelian ratios. Following the third month of age, the Smarca5 mutants, however, displayed rectal prolapses, suggesting the disturbance of immune functions. Gross dissection of the Smarca5 mutant animals revealed severe thymic defects. Thymi from the mutant mice were dramatically reduced in size and weight (Fig. 1D) , which was reflected by a 17-fold reduction in cellularity (Fig. 1E) . Histological evaluation revealed an alteration of thymic corticomedullary architecture (Fig. 1F ) and a higher number of cleaved Caspase-3-positive apoptotic death events in the cortex (Fig. 1G ). The quantification of multiple cortical sections from different animals showed there was a 3-fold increase of apoptotic cells in the cortex of S5 fl/fl hCD2iCre thymi. These observations indicated a developmental defect in thymocytes, accompanied by an increased cell death within the thymi of S5 fl/fl hCD2iCre animals.
To gain insight into the developmental defects of thymocytes, we used flow cytometry of thymic cell suspensions of 4-6-wkold S5 fl/fl hCD2iCre mice. CD4/CD8 immunostaining revealed a marked reduction of DP and CD4-SP cell populations with a corresponding relative increase in DN thymocytes in the mutant thymi ( Fig. 2A) . In absolute counts, the DP cells were depleted by 60-fold, CD4-SP 90-fold, and CD8-SP cells 12-fold, whereas the DN thymocyte population was similar to controls ( Fig. 2B ). Because the Smarca5 allele deletion is completed by the DN3 stage ( Fig. 1B) , we analyzed each subpopulation of DN thymocytes to more precisely determine a stage in which the block of development occurs. CD44/CD25 Ag expression profiles of lineage-negative DN thymocytes revealed a relative increase in DN3 cells to the detriment of DN4 thymocytes (Fig. 2C ). Translated into absolute counts, it was an almost complete absence of DN4 thymocytes in mutants, whereas the DN3 population was present in comparable numbers to controls (Fig. 2D) .
We also examined the impact of Smarca5 deficiency on gd T cell development. Using flow cytometry, we observed that Smarca5deficient animals contain twice as many TCRd + thymocytes (CD4 2 CD8 2 TCRd + ) compared with controls ( Fig. 2E, 2F ). However, out of these TCRd + thymocytes, only 18.4% (compared with 42% in controls) were able to adopt the gd fate ( Fig. 2E) as indicated by the CD73 surface marker that discriminates TCRd + thymocytes committed to the gd lineage (29) . Additionally, the expression of surface CD24, which is normally enriched on immature gd thymocytes and downregulated upon maturation into effector cells (30) , was reduced in Smarca5 mutants ( Fig. 2E) . In contrast to controls, the lower expression of CD24 surface marker observed in the mutants compromised a clear separation of the CD73 + population into immature and mature subsets. The mature gd thymocytes (CD24 low CD73 + ) were further distinguished along the expression of the mutually exclusive CD27 and CCR6 surface markers into IFN-g(CD27 + )-producing or IL-17a(CCR6 + )producing gd subsets (31, 32) . The IFN-g-and IL-17a-producing gd subsets display a subtle imbalance in favor of an IL-17aproducing subset in the Smarca5 mutants ( Fig. 2E ). We conclude that the commitment to gd Developmental blockade in Smarca5-deficient thymocytes is cell autonomous
As hCD2-iCre transgene initiates deletion also in other murine hematopoietic cell subtypes (18) , we tested whether the DN3 to DN4 transition defect is cell autonomous to thymocytes or a result of the impaired thymic microenvironment in which they develop.
Using syngeneic transplantation, we assessed the ability of control BM (marked by CD45.1 isoform) to repopulate thymocytes in lethally irradiated S5 fl/fl hCD2iCre mice (marked by CD45.2 isoform) and vice versa. At day 35 after transplantation, we observed that engrafted thymocytes from controls (CD45.1) developed normally to produce CD4/CD8 double and SP cells in the thymic microenvironment of S5 fl/fl hCD2iCre (CD45.2) animals (Fig. 3A, 3B ). In turn, the engrafted donor S5 fl/fl hCD2iCre BM-derived thymocytes (CD45.2) recapitulated the developmental defect at DN3 to DN4 transition within the control acceptor animals (CD45.1). These results suggested that the DN3 to DN4 transition became defective independently of the thymic stromal components (of S5 fl/fl hCD2iCre mice) but rather intrinsically to the thymocytes lacking Smarca5. To further settle the point of whether the developmental defect of thymocytes observed in vivo is cell autonomous, we used ex vivo cocultures with a BM-derived stromal OP9/N-DLL1 cell line (19) . Sorted preselection early DN3e cells (small CD4 2 CD8 2 CD25 + thymocytes) were added on the OP9/N-DLL1 cells to evaluate the formation of DN4 and DP thymocytes in a time course of 8 d (Fig. 3C ). Although control DN3e cells apparently proliferated and progressed into more mature developmental stages under ex vivo conditions, the majority of Smarca5-depleted cells were held at the DN3 stage till day 8, and their absolute numbers remained similar to the starting cocultures ( Fig. 3C,  3D) . Thus, the outcome of the ex vivo experiment was highly reminiscent of the phenotype of S5 fl/fl hCD2iCre mice. We used yet another approach to test whether the defect of DN3 to DN4 transition could have emerged from a secondary effect, mainly because the DN3e thymocytes in the OP9/N-DLL1 cocultures were sorted from S5 fl/fl hCD2iCre mice with the potentially impaired thymic microenvironment. We isolated LSK BM hematopoietic progenitors from S5 fl/fl hCD2iCre or control mice and kept them differentiating ex vivo on the OP9/N-DLL1 cells.
Again, both the control as well as S5 fl/fl hCD2iCre-derived hematopoietic progenitor cells developed normally into the DN2 stage (day 9); however, from the 16th day of culture, the S5 fl/fl hCD2iCre thymocytes were progressively underrepresented, and by day 22, the DN3 to DN4 transition defect was revealed ( Fig. 3E, 3F) . Thus, the loss of Smarca5 in developing T cells caused a defect intrinsic to the thymocytes undergoing DN3 to DN4 transition, as evidenced by the cocultures using the OP9 cells, and was not a result of a secondary effect due to impaired thymic stromal components or thymic microenvironment.
Smarca5-deficient thymocytes undergo marked apoptosis and proliferation impairment
We next investigated whether reduced cell numbers in S5 fl/fl hCD2iCre thymi and ex vivo OP9/N-DLL1 cocultures (Figs. 1E, 3D ) may be attributed to premature cell death and/or impaired proliferation. As determined by flow cytometry, the ex vivo cultivation of purified DN3e thymocytes eventually resulted in a gradual increase of Annexin V positivity up to 71% by day 8 that did not exceed 15% in controls (Fig. 4A) , indicating that the loss of Smarca5 induced apoptosis in developing T cell precursors. Similarly, we examined the effect of Smarca5 loss on the proliferation by labeling purified DN3e thymocytes with the intracellular fluorescent dye (CFSE) immediately before plating them on OP9/N-DLL1 cells. As seen in Fig. 4B , the analysis of the CFSE signal dilution indicated that the DN control thymocytes proliferated rapidly ex vivo. Conversely, those DN cells that did survive the ex vivo conditions exhibited a decreased division rate, confirming an impaired proliferation of S5 fl/fl hCD2iCre thymocytes. We then used the BrdU incorporation assay to analyze the ability of Smarca5-depleted cells to progress through the various stages of the cell cycle. After a 3 h pulse of BrdU in vivo, we observed that the percentage of proliferating BrdU + DN3 cells (after exclusion of postreplicative BrdU + events) was almost the same in mutants as in controls (14.8% versus 15.8%), and thus, the G1-to-S progression was not altered after the Smarca5 loss at DN3 stage ( Fig. 4C ). However, the portion of postreplicative cells at this stage, which is defined as strictly diploid BrdU + events (33), was 2.5-fold decreased in mutant DN3 cells. These data indicate that Smarca5-depleted DN3 cells normally enter S phase and begin to replicate their DNA; however, they are limited in completing the cell cycle to re-emerge as G1 cells. Mutant DP cells were also impaired because a substantial fraction of the DP cells became arrested at the G2/M phase (Fig. 4D) . Thus, the developmental defects observed upon the loss of Smarca5 are likely the consequence of cell death and impaired cell cycle progression at late S through G2/M phase. This is in contrast to defects in G1/S checkpoint mechanisms as previously observed in human cancer cell lines upon SMARCA5 knockdown (34) .
Smarca5 mutants undergo pre-TCR signaling and the TCR rearrangement
The accumulation of Smarca5-depleted DN3 cells resembles the phenotype of mice that have a defect in pre-TCR signaling or TCRb locus rearrangement (35) . To test whether the induction of pre-TCR signaling was affected by a loss of Smarca5, we performed i.p. injections of anti-CD3ε Ab into S5 fl/fl hCD2iCre and into RAG1 (Rag1 2/2 )-deficient mice. Anti-CD3ε Ab can mimic pre-TCR signaling in vivo and stimulates preselection DN3 thymocytes to proliferate and differentiate into the DN4 cells even in the Rag1 2/2 mice lacking the TCR b-chain expression http://www.jimmunol.org/ Downloaded from (36) . We observed that the anti-CD3ε Ab stimulated the downregulation of surface CD25 molecules on Rag1 2/2 as well as on Smarca5-deficient DN3 thymocytes (Fig. 5A ), which suggested that pre-TCR signaling pathway was not disrupted after Smarca5 loss. However, we noted that compared with highly proliferating Rag1 2/2 DN cells, the S5 fl/fl hCD2iCre DN cells were almost completely absent at day 2 of treatment ( Fig. 5B ), further confirming the poor survival of differentiating and proliferating Smarca5-deficient DN cells. We next examined the expression of CD2 and CD5 on the DN and DP cells to assess their upregulation upon pre-TCR signaling (37, 38) . Data from flow cytometry show that b-selected DN cells that survived Smarca5 loss are still capable of upregulating the expression of CD2 and CD5 molecules (Supplemental Fig. 1A) . Additionally, at the DP stage, the expression of these molecules was almost identical compared with controls ( Supplemental Fig. 1B) . In summary, the ability of S5 fl/fl hCD2iCre DN cells to upregulate CD2 and CD5 indicated that Smarca5 deficiency in thymocytes does not perturb the pre-TCR signaling.
Next, we analyzed the intracellular expression and rearrangement of the TCR b-chain, another prerequisite for the DN3 to DN4 transition. Analysis of intracellular (i)TCRb expression together with membrane-bound CD28 has been shown as a tool to distinguish between preselection and b-selected DN3 cells that have successfully rearranged their TCRb locus (39) . Using this approach, we observed that mutant DN3 thymocytes contain a significantly reduced fraction of iTCRb + / CD28 + b-selected cells compared with controls ( Fig. 5C ). Conversely, the genomic DNA analysis of the Smarca5 mutant DN thymocytes by quantitative PCR showed that the recombination rate of Db1-Jb1 and Db2-Jb2 gene segments was not altered (Supplemental Fig. 1C ). As determined by RNA-seq analysis of DP cells (see further), the expression pattern of the constant (Trbc) and variable (Trbv) gene segments was similar to controls (Supplemental Fig. 1D ), indicating that Smarca5 deficiency did not abolish the TCRb locus rearrangement. To test whether the defective formation of the b-selected DN3 cells was a result of impaired TCRb rearrangement, we crossed S5 fl/fl hCD2iCre mice with TCRb/a transgenic mice (OT-II). Expression of the fully rearranged TCRb/a construct in OT-II background is able to suppress V(D)J recombination at endogenous loci and also "rescue" thymocyte development in mice lacking essential factors for the TCRb/a rearrangement (40, 41) . Analysis of S5 fl/fl hCD2iCre OT-II animals revealed that expression of the transgenic TCR b/a-chains failed to rescue the Smarca5 knockout phenotype. The absolute and relative counts of DN and DP subpopulations remained similar to the S5 fl/fl hCD2iCre mice ( Fig. 5D -F). Particular exceptions were mature SP thymocytes, where the CD4 SP cells whose 3-fold increase to the detriment of the CD8 SP cells likely reflected the positive selection of thymocytes toward CD4 lineage that normally occurs in the OT-II strain (Fig. 5D ). Thus, rather the poor survival of b-selected DN cells than defects in pre-TCR signaling or TCRb locus rearrangement could best explain the phenotype of S5 fl/fl hCD2iCre mice.
As the surface expression of TCRb in DP thymocytes is essential for the production of SP subpopulations, we focused on stages beyond DN3 to decipher how Smarca5 deficiency influenced the TCRb expression. Normally, the surface expression of TCRb is low or none in the DN3 stage, becomes induced at the DN4 stage, and further upregulated in SP thymocytes. We examined the level of surface TCRb expression on individual developmental stages of thymocytes and mature peripheral T cells in the spleen. We observed that surface TCRb expression was detectable in all developmental stages from a subfraction of DN3 (low expression) to mature SP populations (high expression) in both Smarca5-deficient as well as control thymocytes (Fig. 5G,  Supplemental Fig. 1E ). However, the fraction of cells with upregulated TCRb expression was reduced within each analyzed Smarca5-deficient thymic subpopulation compared with controls. Taken together, Smarca5-deficient thymocytes are able to express and upregulate the surface TCRb expression during their development with an exception at the DN4 stage that almost lacks fraction of TCRb-positive cells.
Smarca5 deficiency altered the developmental program of postb-selection stages
It has been shown that during differentiation from DN to DP stage, the ACF complex containing Smarca5 and Acf1 represses, in cooperation with Satb1, the Il2ra (CD25) gene (12, 42) . Indeed, flow cytometry indicated that DP cells of S5 fl/fl hCD2iCre mice inappropriately express both CD44 and CD25, the markers of earlier developmental stages. Whereas the CD25 molecule becomes partially downregulated, the CD44 remains upregulated in DP cells, implicating the dysregulation of early expression programs (Fig. 6A ). Our previous studies suggested that Smarca5 participates in the regulation of gene expression programs associated with survival and differentiation of lens, cerebellum, and hematopoietic progenitor cells (10, 17, 43) . To gain a global view on the gene expression programs dysregulated by Smarca5 loss in b-selected thymocytes, we purified DP cells from S5 fl/fl hCD2iCre mice and used RNA-seq to compare the gene expression profiles with those from control DP cells. Of .21.500 expressed genes, a total of 3.318 transcripts were differentially expressed with false discovery rate (FDR) ,0.05 and BaseMean value .10. From these, 1.503 mRNAs were (,2-fold) downregulated and 1.815 mRNAs were (.2-fold) upregulated. Gene ontology analysis of the differential expression using gene set enrichment analysis (GSEA) (44) showed the enrichment of mRNAs involved in expected categories such as apoptosis and the p53 pathway; however, most of them were either immunologic or lymphocyte associated (Fig. 6B) . By dividing the differentially expressed genes into previously published mRNA clusters with similar behaviors during thymocyte differentiation (45), we observed http://www.jimmunol.org/ Downloaded from that the group of upregulated genes in the mutant DP cells overlapped to those mRNAs that peaked in expression at the early (DN1-DN2) or pre-b-selection DN3a stage (Fig. 6C ). Such genes were, for example, receptors (Il7r, Ctla4, Ptcra, Ly6a and also Il2ra/Cd25 and Cd44), signaling molecules (Dtx1, Hes1, Notch1, Lfng, Rab44), and transcription factors (Irf7, Tcf7l2, Spib) ( Fig. 6D) . Accordingly, the group of downregulated genes (total 97) fall into the category of genes that are gradually expressed by b-selected cells during the transition into DP, such as transcription factors (Klf7, Ets2, Ikzf3, Bcl6), surface molecules (Plxnd1, Slamf1, Cd81), signaling (Themis), and others (Tdrd5, Cacna1e). To evaluate whether the mutant DP cells more closely resembled pre-or post-b-selected cells, we used a previously published transcriptome analysis of microarray data of wt C57BL/6J DN3a and DP stage cells (45) and created two sets of the 200 most upregulated and downregulated genes in wt DN3a compared with wt DP stage (Supplemental Fig. 2A ). Hence, the GSEA analysis of mRNAs dysregulated upon Smarca5 deficiency revealed a strong enrichment of upregulated (normalized enrichment score = 2.37, FDR ,0.001) and downregulated (normalized enrichment score = 22.53, FDR ,0.001) mRNAs of the wt DN3a stage (Fig. 6E ). This finding indicates that although Smarca5-deficient cells express post-b-selection surface markers (e.g., CD4, CD8, CD5, CD2) as normal DP cells, RNA-seq data reveals that they retain a transcriptional program of pre-b-selection DN cells. Thus, Smarca5 ablation greatly disorders the developmental programming of T cell progenitors.
Smarca5 is required for pro-B/pre-B transition of B cell progenitors
Additional analysis of S5 fl/fl hCD2iCre mice revealed also a dramatic reduction of the spleen cellularity ( Fig. 7A ). Besides the reduction of splenic T cells and NKT cells, which both developed in the thymus from the CD4 + CD8 + DP precursors (46) , we also observed a marked depletion of B lymphocytes, whereas the numbers of myeloid cells were not significantly altered (Fig. 7B, 7C ). Indeed, immunohistochemistry of mutant spleens showed a prominent follicular hypoplasia affecting both T cell as well as B cell zones ( Fig. 7D ), suggesting also a defect in the B cell development of S5 fl/fl hCD2iCre mice. To investigate a stage at which the developmental defect occurred, the early B cell progenitor populations from BM were analyzed. Flow cytometry analysis revealed an almost complete loss of pre-B cells (B220 + CD43 2 ) in mutants, whereas the proportion of pro-B cells (B220 + CD43 + ) was virtually unperturbed (Fig. 7E ). Closer examination of the pro-B population showed a developmental arrest between early preselected pre-B-I cells (CD117 + ) and pre-B-II (CD25 + ) cells that underwent productive IgH gene loci rearrangement (47) . Taken together, Smarca5 deficiency affects development of early B220 + CD43 + pro-B cells in BM, implicating the requirement of Smarca5 for both early T as well as B lymphocyte development. It has been previously noted that deletion of Smarca5 gene in hematopoietic progenitors induces the expression of p53 transcriptional targets (10) . Our current RNA-seq data suggested that increased cell death and impaired cell cycle progression of thymocytes coincide with the activation of the p53 program ( Fig. 8A) . To test the biological significance and requirement of the Trp53 gene for the Smarca5 mutant phenotype in developing lymphocytes, we used an additional mouse strain homozygous for the Trp53 null allele (48) to create the S5 fl/fl hCD2iCre Trp53 2/2 mice. Interestingly, the Smarca5 deletion slightly prolonged the survival of the Trp53 knockout mice (Fig. 8B ). We observed that the introduction of the Trp53 knockout allele improved thymic cellularity of the Smarca5deficient mice (Fig. 8C ). Flow cytometry analysis revealed a proportional increase (from 26.3 to 55.1%) as well as absolute cell number expansion (4-fold) of the double knockout DP population (Fig. 8D, 8E) , whereas the absolute numbers of DN cells were unchanged, indicating a DN to DP transition rescue (Fig. 8E, 8F) . We performed RNA-seq of samples derived from the double knockout DP cells and compared gene expression profiles with previous data. Expression analysis confirmed that the p53 targets, especially those that are associated with the induction of apoptosis in response to DNA damage such as p21/Cdkn1a, Noxa/Pmaip1, and Bax, were upregulated specifically in the Smarca5-deficient DP cells, whereas upon the introduction of the Trp53 2/2 allele, their expression became normalized (Fig. 8G) . Although the thymic cellularity in double knockouts was partially recovered, we still observed markedly dysregulated expression of the mRNAs connected to normal thymocyte development ( Supplemental Fig. 2B) . Thus, the activation of p53 targets was rather a modifier of the severity of the phenotype and not contributory to differentiation defects observed in S5 fl/fl hCD2iCre mice. Indeed, flow cytometry analysis showed that Smarca5 and Trp53 double knockout DP cells contained up to a 3.5-fold excess of H3S10 phos positive (mitotic) cells as compared with single Smarca5 knockout (Fig. 8H) . However, the G2/M blockade in the DPs of the Smarca5 and Trp53 double knockout mice persisted (Supplemental Fig. 2C ).
To test whether the p53 loss could also recover the development of early B cell progenitors, BM cells from S5 fl/fl hCD2iCre mice with or without Trp53 2/2 loci were analyzed for the expression of B220 and CD43 molecules. However, unlike the partial rescue observed in the thymocyte compartment, the data from flow cytometry show that the p53 loss failed to rescue the survival and/or maturation at pro-B (B220 + CD43 + ) to pre-B stage (B220 + CD43 2 ) transition ( Fig. 8I ). To conclude this part, the introduction of the Trp53 knockout allele into the Smarca5-deficient strain significantly improved the proliferation and/or survival of thymocytes but not of early B cells. Importantly, the rescue experiment was unable to restore the dysregulated differentiation pathways in both B and T lineages.
Discussion
Although the SWI/SNF and CHD chromatin-remodeling factors have been implicated in the regulation of lymphocyte progenitorspecific transcription and differentiation (6, 49) , the role of ISWI proteins in the development of early T and B cells has not been addressed. This study brings yet unknown evidence that the ISWI ATPase Smarca5 regulates early lymphocyte development by promoting stage-specific gene expression and, secondarily, cell survival and proliferation. Interestingly, the role of Smarca5-containing remodeling complexes was previously implicated in the DNA double-strand break (DSB) repair in human immortalized cell lines (50, 51) . These reports showed that SMARCA5 is rapidly recruited to DSBs, and the knockdown of SMARCA5 sensitizes cells to DNA damage. SMARCA5 protein was shown recruited to the sites of DSB by histone deacetylase Sirtuin 6 (SIRT6) (51) . Additional pathways and interaction partners of Smarca5 participating at the sites of DNA damage were also established (52, 53) . Thus, Smarca5 seemed to be a suitable candidate for testing its in vivo role in lymphocytes, in which the developmentally programmed DSBs occur. Indeed, our data showed that S5 fl/fl hCD2iCre mice initially exhibited a marked reduction of those early progenitors that productively rearranged Ag receptor loci, the TCRb expressing DN3 thymocytes ( Fig. 5C ) and B220 + CD43 + CD25 + early B cells (Fig. 7E) . Coincidently, the upregulation of p53 target genes (Fig. 8G ) and the partial recovery of thymus cellularity in the S5 fl/fl hCD2iCre Trp53 2/2 mice (Fig. 8C ) could also be interpreted as Smarca5 being involved in the DSB repair during the Ag receptor gene rearrangement. However, further experiments challenged this view. The developmental defect, at least in thymocytes, could not be attributed mainly to the DSBs repair aberration, as the OT-II transgene was unable to rescue the DN3 to DN4 transition defect of Smarca5-deficient cells (Fig. 5D) . Notably, the data from RNAseq showed that the expression pattern of the constant (Trbc) and variable (Trbv) gene segments was similar compared with the control DP cells (Supplemental Fig. 1D) , indicating that the relative use of the different gene segments during TCRb rearrangement was not affected in the mutants. In addition, the S5 fl/fl hCD2iCre Trp53 2/2 mice displayed a comparable life span as S5 fl/fl Trp53 2/2 mice (Fig. 8B) , which is contrasting to the mouse knockout models of genes employed directly in the NHEJ that upon codeleting with the Trp53, accelerated tumorigenesis with shortened animal survival (54) . Thus, the Smarca5 deletionmediated maturation defect is not primarily mediated via the disrupted repair of developmentally programmed DSBs.
Generally, except in the SP CD8 and CD4 T cells that expressed a lower level of surface TCRb (Fig. 5G, Supplemental Fig. 1E ), the iTCRb expression and proximal pre-TCR signaling seem to be preserved in the Smarca5-deficient mice as S5 fl/fl hCD2iCre DN3 cells gave rise (albeit with a very low rate) to some DP-like cells and could be normally stimulated by anti-CD3 Ab. The DN3 stage and all the following developmental stages were considerably altered in the S5 fl/fl hCD2iCre mice. Once Smarca5 was inactivated, b-selected DN3, DN4, DP, and also pre-B cells lost their ability to accumulate and became depleted. Smarca5 loss leads to a marked increase in the number of cells undergoing apoptosis (Fig. 1G ). Our data indicate that this was not caused by the induction of a generalized apoptotic response as resting DN3e cells displayed very low level (up to 5%) of cell deaths even after 6 d of ex vivo cultivation (data not shown). This result, together with the observation that Smarca5-deficient DN3 stage lacks postreplicative cells (Fig. 4C) , rather suggested that the disruption of Smarca5 function triggers apoptosis of highly proliferating cells and especially those that have already entered the S phase. Others reported that depletion of Smarca5 in murine lens (using Le-Cre system) results in a reduction of BrdU and Ki67 positive presumptive lens epithelial cells, leading to the lens developmental defect (43) . Also, the early deletion of Smarca5 in cerebellar progenitors (using the Nestin-Cre system) resulted in a lower number of BrdU-positive Purkinje cells and of granule neuron progenitors at E17.5, possibly because of massive cell death (17) . Moreover, the defective S phase progression in the DN3 stage could also explain the formation of G2/M-arrested S5 fl/fl hCD2iCre DP cells (Fig. 4D) . In the erythroid cell compartment, the Smarca5 loss caused the emergence of tetraploid cells permanently exiting the cell cycle in populations of highly proliferating proerythroblasts-to-basophilic erythroblasts (10) . This, along with a substantial number of apoptotic events, was interpreted mainly as a consequence of the activation of the DNA damage-associated p53 program. Indeed, stressed replicating cells activate their replication checkpoint to delay S phase progression and G2/M transition (55) . The p53 and its downstream molecules are then required to maintain a G2 or tetraploid G1 arrest, which afterward promotes cell senescence (56) (57) (58) . However, although S5 fl/fl hCD2iCre DP cells also upregulated some proapoptotic (Noxa, Bax, Puma) and cell cycle regulating (Cdkn1a/p21) p53 target genes, the rescue of phenotype was incomplete, and the tetraploid events were still present in the Smarca5 and Trp53 double knockouts (Supplemental Fig. 2C) , indicating that the cell cycle arrest and induction of apoptosis were predominantly p53 independent. We hypothesize that the dysregulated expression of the stagespecific mRNAs (including the surface markers) in Smarca5depleted b-selected cells stay behind the thymocyte defects observed in the S5 fl/fl hCD2iCre mice. Indeed, the ablation of chromatin remodelers Brg1 or Chd4/Mi-2b leads to differentiation defects, cell cycle arrest, or apoptosis in b-selected thymocytes partially because of dysregulated gene expression (reviewed in 59). Unlike the Brg1 or Chd4 chromatin remodelers that regulate differentiation from DN4 to DP stages (60, 61) , the Smarca5 knockout phenotype appears early and is relatively unique as the pre-b-selected DN3 cells lacking Smarca5 are unable to downregulate marker molecules (CD25, CD44). Among the mechanisms behind inappropriate CD25 molecule expression might be the previously reported participation of Smarca5 in the Satb1directed repression of Il2ra/Cd25 loci (12, 42) . Genome-wide characterizations of binding into chromatin by chromatin immunoprecipitation sequencing revealed that Smarca5 is enriched mostly at the gene promoters and the regulatory regions (62, 63) . Transcriptome analysis by RNA-seq confirmed a considerable number of ectopically expressed transcripts associated with b-selection and also genes that were not activated and remained downregulated during the transition into the DP stage ( Fig. 6D ), suggesting that the absence of Smarca5 disables a crucial component of the b-selection transcription machinery. The function of Smarca5 as a transcriptional activator and repressor was shown in studies using murine EL4 T lymphoma cell line upon small interfering RNA-mediated depletion. Although Smarca5 participates in repression of IL genes, including Il2, Il5, Il13, Il17a, and in activation of Il3 after stimulation with PMA and ionomycin (13), we have not observed this during the transition into the DP stage as those ILs are expressed mainly by mature T cells. Perturbation of Smarca5 functions may have also affected other profiles during the transition from pre-to post-b-selected DN3 thymocytes by dysregulating genes related to proliferation, metabolism, and b-selection (45) . To conclude, Smarca5 represents an important transcriptional regulator that participates indispensably during early T cell development. To further address the role of Smarca5 in regulating T cell promoters, we are currently preparing a transgenic mouse line with tagged Smarca5 protein.
Introduction
Control of tumor suppressor gene expression requires cooperation of epigenetic factors and represents crucial yet not fully understood events in leukemogenesis. Ctcf is a key epigenetic regulator and zinc-finger transcription factor, whose binding to DNA can be prevented by DNA methylation [1] . Ctcf regulates the well-established imprinted H19/Igf2 locus by blocking communication between the Igf2 promoter and its enhancer leading to increased transcription of H19 on the maternal allele. Ctcf association within a cohesin complex at the H19/Igf2 locus enables long-range chromatin interactions [2] and efficient enhancer blocking [3] on the unmethylated imprinting control region (ICR) of the maternal allele [4] . Several reports indicated Ctcf involvement in hematopoiesis [5] [6] and leukemogenesis [7] . However, the mechanisms by which Ctcf regulates these processes are not well understood.
Smarca5 (Snf2h), is an epigenetic chromatin-remodeling factor that assembles and slides nucleosomes along the DNA fiber. Smarca5 together with a bromodomain-containing protein WCRF180 has been demonstrated to load the Cohesin complex onto DNA [8] . Expression patterns of Ctcf and Smarca5 (together with the Cohesin complex) overlap in hematopoietic progenitor cells (www.biogps.org). Moreover, Smarca5 is required for proliferation and/or differentiation of immature hematopoietic progenitors with extensive cytokine-induced proliferative capacity [9] and is upregulated in acute myeloid leukemia (AML) blasts [10] .
The transcription factor PU.1 (SPI1, Sfpi1) is a key regulator of hematopoiesis. The expression levels of PU.1 are precisely controlled by several myeloid transcription factors, including PU.1 itself [11] , through interactions at an upstream regulatory element (URE) and the promoter [12] . The URE directs .80% of PU.1 expression (dependent on cell type) and its deletion in mouse or inactivation by a provirus leads to AML [13] . Additional enhancers between the URE and the SPI1 promoter have been suggested to regulate long-range interactions at the SPI1 locus [14] . Our recent work demonstrated that the URE is methylated in a subset of Myelodysplastic syndrome (MDS) and AML patients. Moreover, demethylation by 5-azacitidine (AZA) treatment increased PU.1 expression and induced myeloid differentiation [15] . This suggests that the SPI1 gene in AML may become epigenetically dysregulated due to defective binding of factors that recognize unmethylated DNA.
We herein show that CTCF together with SMARCA5 and members of the Cohesin complex associate with the SPI1 gene in normal myeloid cells, but this interaction is disrupted in AML blasts. Upon DNA demethylation in leukemia cells, the recruit-ment of CTCF and its binding partners is partially restored. Moreover, CTCF binding is newly established at the 214.4 Enhancer leading to a block in PU.1 expression. Thus in leukemia cells, AZA exposes newly hypomethylated sites to CTCF that together with SMARCA5 bind and control PU.1 expression.
Materials and Methods
Cell Lines
MEL cells were cultured as described elsewhere [16] and transfected (DMRIE-C, LifeTech.) with 25 nM siRNA-CTCF or non-silencing control siRNA (L-044693-01, Dharmacon). Stable transgenic Smarca5-shRNA cells were kindly obtained from Prof. Arthur. I. Skoultchi Laboratory. shSmarca5 was activated with 1 mg/mL of doxycycline. 2610 6 OCI-M2 cells [15] (DSMZ) were transfected (Amaxa) with 20 pmol siRNA-hSMARCA5 (s16082, Ambion, control: #1-AM4611), or with 0,5 mg pCTCF (Origene) or pBSK+ plasmid negative control. OCI-M2 were treated with 5 mM AZA (3-doses in 72 hrs) in presence of granulocyte colonystimulating factor (G-CSF) (50 ng/ml) [15] .
Primary Samples
Written donor's informed consent (based on 1964 Declaration of Helsinki) was obtained. The Ethics Committee of the General Faculty Hospital and First Medical Faculty, Charles University approved the project. CD34+ cells were magnetically separated and their quality assessed by flow cytometry (purity .95%). Bone marrow samples from two AML patients with dysplastic features and two advanced high-risk MDS were utilized (see Table S1 ). Normal CD34+ cells were magnetically separated from normal donor peripheral blood. Mixed myeloid cells were unfractionated peripheral blood mononuclear myeloid cells derived from G-CSF-mobilized donors in complete remission of lymphoma. Mixed myeloid cells exceeded 95% (as determined by differential blood count) of granulocytes, monocytes and their precursors. Depletion of erythrocytes was done by ammonium chloride. : Table S2 ).
RNA and Protein Assays
Western blot lysates (RIPA) were gently (361 s) sonicated on Branson Sonic Dismembrator (model 500) with a micro-tip. SDS-PAGE was run, dry-blotted and incubated with antibodies: anti-Smarca5 (cat.# 07-624, Upstate, 1:500), anti-Ctcf (cat.# 07-729, Upstate, 1:5000), anti-PU.1 (sc-352, Santa Cruz, 1:600), secondary-HRP-conjugated anti-rabbit (cat.# 80919, Jackson Immu-noResearch, 1:4000), HRP-conjugated anti-actin (I-19), sc-1616; Santa Cruz).
Nuclear immunostaining was done with anti-Smarca5 (cat.# MAB3644, Chemicon, 1:200), anti-Ctcf (cat.# sc-28198, Santa Cruz, 1:500), secondary antibodies (cat.# A-11020, LifeTech., 1:300 or cat.# A-11070, 1:300). Heterochromatin staining: Vectashield Mounting Medium containing 49,6-diamidino-2phenylindole (DAPI). Confocal laser scanning microscopy: Leica TCS SP2 with AOBS system.
Enhancer-blocking Assay
The reporter vectors pIHLE, pIHLME and pIHLIE are based on the pGL3 luciferase reporter plasmid (Promega). The vectors were generated and kindly provided by Prof. Mitsuyoshi Nakao from Kumamoto, Japan. The reporter assay has been described previously [17] [18] . For knockdown experiment the HeLa cells were co-transfected with siRNA targeting CTCF, SMARCA5 or non-specific siRNA together with reporter vectors and Renilla luciferase control plasmid using lipofectamine (Invitrogen). The cells were lysed 96 hrs after transfection and analyzed using Dual Luciferase Assay and luminometer Glomax (all Promega). Firefly activity was normalized on Renilla luciferase activity.
DNA Methylation, Co-IP and ChIP
Genomic DNA was treated using bisulfite, amplified (primers in Table S2 ), and subcloned. DNA from clones (.10 clones/ amplicon) was sequenced as described elsewhere [15] .
For co-IP, 6610 6 MEL or K562 cells were lysed (RIPA) and gently sonicated. 100 mg of precleared protein extract was incubated 3 hrs/4uC with anti-Ctcf (cat#07-729) or anti-Smarca5 (cat#07-624, Upstate) and next with proteinA/proteinG overnight. Control antibody: IgG, cat.# NI01, Calbiochem, 5:100). Immunoprecipitates (IP) were washed with set of buffers. IPbuffer (0.02% SDS/2%Trion X-100/4 mM EDTA/40 mM Tris-HCl (pH = 8)/300 mM NaCl), WashI (0.1%SDS/1%Triton X-10/ 2 mM EDTA (pH = 8)/20 mM Tris-HCl (pH = 8)/50 mM NaCl), WashII (0.1% SDS/1% Triton X-10/1% EDTA (pH = 8)/ 20 mM Tris-HCl (pH = 8)/500 mM NaCl). IPs were resolved on SDS/PAGE, blotted, and immune-detected.
Chromatin immunoprecipitation (ChIP) [19] lysates were controlled for DNA purity&quantity by Nanodrop ND-1000. Antibodies: Smarca5/Snf2h (cat.#ab3749, Abcam, 3 mg/IP), Ctcf (cat.#ab10571, Abcam, 2 mg/IP), RAD21 (cat.#ab992, Abcam, 2 mg/IP), and SMC1 (cat.# ab9262, Abcam, 2 mg/IP). Control IgG: cat.#NI01, Calbiochem, 5:100.
Results
Smarca5 Regulates Ctcf Recruitment onto the ICR Region
The role of Ctcf was previously well documented in mouse epigenetics [1] and it was suggested to regulate differentiation of leukemic cells [5] . To test whether in AML blasts Ctcf binds at the ICR and regulates the expression of the H19 and Igf2 genes, we first used mouse erythroleukemia (MEL) cells. MEL cells express the H19 mRNA and the Igf2 mRNA, albeit at approximately 1000-fold lower level ( Figure S1 ), indicating that Ctcf may associate with the ICR of H19/Igf2. Indeed, Ctcf was detected at the ICR by ChIP at four neighboring amplicons (23.7, 23.1, 22.6, 22.2 kb relative to H19 TSS) in MEL cells ( Figure 1A , white bars). Detection of Ctcf at the ICR was specific as indicated by its depletion following Ctcf knockdown ( Figure 1A, black bars) . Efficiency of the Ctcf knockdown was confirmed using Western blots ( Figure 1E right panel) .
Ctcf has been proposed to require epigenetic remodeling and that the ICR is regulated by interplay between Ctcf and putative nucleosome-remodeling factors and DNA methylation machinery within the ICR [20] [21] . As such, we tested the involvement of the ISWI nucleosome assembly and sliding ATPase, Smarca5 at the ICR. We used MEL cells with a stably integrated doxycycline (Dox)-dependent Smarca5-shRNA construct. Using ChIP we established Smarca5 occupancy at the ICR coincidently with Ctcf ( Figure 1B white bars) . Efficiency of Smarca5-shRNA was confirmed on mRNA ( Figure S2 ), protein ( Figure 1E left) and occupancy ( Figure 1B) levels. In addition, using different antibody we again detected Smarca5 occupancy at the ICR (Figure 1D , white bars). Outside ICR we tested number of loci where occupancy of either Smarca5 of Ctcf was not detected (data not show). As Ctcf and Smarca5 coincidently occupied the ICR it suggested that Ctcf may recruit Smarca5 onto the DNA. Another possibility was that Smarca5 recruited Ctcf or alternatively, Ctcf is recruited alone but interacts with Smarca5 that was recruited to the DNA by other mechanisms. To elucidate these possibilities the ChIP was performed on the ICR locus upon Smarca5 knockdown. Figure 1C shows that downregulation of Smarca5 resulted in depletion of the Ctcf occupancy. We next asked whether Smarca5 occupancy is in turn dependent on Ctcf. Surprisingly, upon siRNA-mediated CTCF knockdown we observed that occupancy of Smarca5 was stable (at one amplicon) or increased upon siRNAmediated depletion of Ctcf ( Figure 1D ). Thus it is likely that Ctcf recruitment to its DNA binding sites at the ICR is dependent on the presence of Smarca5.
We next tested whether there is an interaction between Ctcf and Smarca5 by a co-immunoprecipitation assay. Indeed, antibody to Smarca5 was able to precipitate Ctcf protein from total lysates as revealed by immunoblotting using antibody to Ctcf (Figure 1F  right) . Conversely, the antibody to Ctcf immunoprecipitated the Smarca5 protein that was further revealed on the Smarca5 immunoblot ( Figure 1F left) . According to antibody datasheets, the signal for both Ctcf and Smarca5 consists of one dominant band and also inconsistently appearing additional less frequent bandsignals upon high exposure. To establish Ctcf-Smarca5 interaction in erythroleukemias the co-IP was reproduced also in additional AML-erythroleukemia cell line (human K562 cells, Figure S3 ). To test Ctcf-Smarca5 interaction on cellular level the confocal microscopy of MEL nuclei was used and it revealed partial overlap of intensity profiles ( Figure S4 ). To summarize this part, using ChIP, co-IP, and additional approaches in transformed blasts with the use of knockdown experiments: the Ctcf and Smarca5 interaction in AML-M6 was revealed.
SMARCA5 Functionally Cooperates with CTCF
To test whether SMARCA5 is capable of regulating CTCFmediated transcriptional outcome we utilized reporter assays with the vectors pIHLE, pIHLME and pIHLIE, as described previously [17] [18] . Briefly, while pIHLE contains the H19 promoter and enhancer and its activity is not affected by CTCF, in the pIHLIE the ICR insulator is placed between the promoter and enhancer and upon CTCF binding it efficiently blocks transcriptional activity of the reporter. pIHLME is similar to pIHLIE with exception of CTCF-binding site mutation (Figure 2A ). While transcriptional activity of pIHLIE is inhibited in presence of CTCF, the pIHLME activity is 3-fold higher ( Figure 2B ). To test requirement of SMARCA5 in the CTCF-mediated enhancerblocking reporter system we inhibited SMARCA5 by siRNA and determined luciferase activity of the above-mentioned plasmids transiently transfected into the HeLa cells. Indeed, upon knockdown of either CTCF or SMARCA5 the reporter activity was significantly increased ( Figure 2C ). Therefore, SMARCA5 is an important epigenetic factor required for CTCF enhancerblocking activity (see also Figure 2A , at the bottom).
Smarca5 Regulates Transcriptional Outcome of Ctcf Target Genes
We next asked whether manipulation of the Ctcf and Smarca5 would result in changes of Igf2/H19 gene expression. MEL cells depleted of Smarca5 or Ctcf were analyzed by RT-PCR for mRNA expression. As expected [1] , knockdown of Ctcf decreased levels of H19 (5-fold) and increased levels of Igf2 expression (7.5fold) ( Figure 3A) . Similarly, knockdown of Smarca5 resulted in similar effects, downregulation of H19 (3-fold) and upregulation of Igf2 (10-fold) ( Figure 3B ). Thus, downregulation of Ctcf or Smarca5 result in similar transcriptional outcomes of the Ctcf target genes. This observation complements ChIP and reporter data and indicates that Smarca5 enables Ctcf to bind to ICR and stimulate H19 expression while inhibiting Igf2 transcription.
We next asked whether Ctcf/Smarca5 regulates genes directly involved in hematopoiesis and leukemogenesis. Sfpi1 is a predicted CTCF-target gene and at the same time a well-known transcriptional master regulator of myelopoiesis [22] . It is known that Smarca5 is overexpressed in leukemic cells including MEL cells [10] . PU.1 is also expressed in MEL cells however its level is not downregulated therefore inhibiting the erythroid program. Coincidently such PU.1 level is not sufficient for inducing and completing the myeloid program whereas upon its further increase the MEL cells are capable of propagating the myeloid program [19] . Therefore, we used Smarca5 knockdown approach and tested effect of Smarca5 downregulation on expression of PU.1 and its target Cebpa. Indeed, shRNA-mediated downregulation of Smarca5 in MEL cells resulted in significant upregulation of PU.1 (and Cebpa) on mRNA ( Figure 3C ) and protein ( Figure 3D ) levels indicating that Smarca5 may regulate PU.1 levels in blasts.
CTCF/SMARCA5 are Recruited at Additional CTCF Target: SPI1 Gene
As shown in Figure 4A , the human SPI1 gene contains several highly conserved regions upstream from the TSS that contain previously described enhancers [14] . First, we asked whether CTCF and SMARCA5 occupancy are detectable in normal human myeloid cells. Using ChIP we focused on loci with more than 2-fold occupancy relative to control antibody. We identified diffuse occupancy of CTCF with peaks involving amplicons 216.6 (downstream URE), 214.4 (Enhancer), and 211 (Element) as well as in the neighboring amplicons: 215. 6, 213.7, 213.4, 213.3, 212.4 and also close to the promoter at 20.15 ( Figure 4B , grey bars). SMARCA5 occupancy was found also rather diffuse involving peaks from 217.5 to 215.3 (at URE and downstream URE) and at 211 (Element) and to lesser extent in the neighboring amplicons ( Figure 4B , dark bars).
Next we tested CTCF and SMARCA5 occupancy at SPI1 gene in human AML blasts of OCI-M2 cell line. SPI1 gene was previously shown to be DNA-methylated in OCI-M2 and PU.1 expression is very low [15] . Not unexpectedly, CTCF was localized in just one of the 14 used amplicons near the SPI1 promoter at 20.15 ( Figure 4C , white bars). We observed distribution of SMARCA5 in AML blasts that was similar to mixed myeloid cells: from 217.2 to 215.6 (at URE and downstream URE) and at 211 (Element) ( Figure 4D , white bars). Correspondingly to our knockdown experiments ( Figure 1D ) To test whether demethylation of SPI1 gene would facilitate CTCF recruitment we used AZA treatment of OCI-M2 as we described recently [15] . Indeed demethylation of SPI1 gene resulted in CTCF recruitment ( Figure 4C, black bars) . Strikingly, the CTCF recruitment induced by AZA was specifically localized at 214.4 (Enhancer). A trend towards CTCF occupancy is also seen at 215.6 and 211 (Element) that corresponds to CTCF occupancy in the mixed myeloid cells. AZA treatment facilitated SMARCA5 recruitment at the regulatory region of SPI1 gene and overlapped with CTCF recruitment at 214.4 Enhancer ( Figure 4D , black bars). In addition, the amplicons 215.6, 213.4, and 211 (Element) showed spread signal of SMARCA5. To conclude this part, CTCF and SMARCA5 co-occupy its newly validated target SPI1 using ChIP assay at the 214.4 Enhancer upon AZA-mediated DNA demethylation.
Cohesin Members Co-occupy the SPI1 Gene with CTCF and SMARCA5
As stated in the introduction section, CTCF fractionates as part of the Cohesin complex. We asked whether this CTCF-Cohesin fraction is enriched at the SPI1 gene. Using ChIP we tested occupancy of RAD21 and SMC1 using experimental conditions described in part 3 above. Occupancy at the SPI1 regulatory regions by RAD21 and SMC1 was very similar. In normal human myeloid cells, RAD21 and SMC1 co-occupy the URE as indicated by amplicons 217.5 to 215.6. The second highest occupancy for RAD21 and SMC1 was observed at amplicons 211 (Element) and 29.7 ( Figure 5A ).
We next determined occupancy of RAD21 and SMC1 in AML blasts (OCI-M2) with or without previous AZA treatment. Indeed, lack of CTCF in OCI-M2 resulted in negligible occupancy of both RAD21 and SMC1 at the SPI1 gene. Upon AZA treatment, RAD21 was recruited to 215.9, just upstream of CTCF and SMARCA5 binding at 215.6 ( Figure 5B) . Moreover, the signal spreads upstream towards the URE, together with SMARCA5. In addition, RAD21 was also recruited at 211 Element (where CTCF and SMARCA5 are also recruited) and at the 29.7 amplicon. SMC1 recruitment was observed only at one amplicon, at 217.2 at the URE (together with RAD21) ( Figure 5C ). Importantly, recruitment of CTCF and SMARCA5 at 214.4 Enhancer was not overlapped by RAD21 or SMC1 indicating that the Cohesin complex was not involved at this CTCF binding site.
CTCF/SMARCA5 Binding Site at SPI1 Gene is Methylated in AML and Demethylated upon AZA
To associate the DNA methylation status at the 214.4 Enhancer with CTCF occupancy, we used a sequencing approach of bisulfite-treated DNA. First, we mapped the CTCF binding site ( Figure 6A ) and determined the methylation status in AML CD34+ cells compared to normal CD34+ cells and mixed myeloid cells. Unlike its normal counterparts where the percentage of unmethylated DNA ranges from 70-100%, the MDS/AML progenitors showed a low level of unmethylated DNA ranging from 10 to 40% ( Figure 6B ). Interestingly, we compared effects of AZA treatment on the methylation status at the 214.4 Enhancer and observed that a patient treated with AZA contains more unmethylated CpGs compared to a patient who is not treated by demethylation therapy (Figure 6C ). Effect of AZA at 214.4 on OCI-M2 is shown in Figure 6D . CTCF binding site is demethylated by 5% at CGs #7 and #8 and by 22% at CG #6. Compared to URE [15] , where the effect of demethylation is very effective, in the 214.4 Enhancer the demethylation is less pronounced. At two additional CGs #9 and #10 downstream the CTCF binding AZA was unable to decrease DNA methylation. Complete set of DNA methylation data in OCI-M2 at 214.4 (where CTCF is enriched) and in the neighboring regions (215.6 and 211, where CTCF enrichment shows trend towards significance) are shown in Figure S6A . In MDS patients treated with AZA the 214.4 Enhancer is a target of AZA-mediated demethylation (in CD34+ progenitors) within up to 6 neighboring CGs including those found in OCI-M2 (indicated by arrows, see Figure S6B ). Interestingly, normal CD34+ cells display up to 10 demethylated CGs of the 214.4 Enhancer as compared to CD34+ cells from MDS/AML patients ( Figure S6C ). However, we didn't detect these remarkably consistent DNA demethylation changes in other two regions (215.6 and 211 Element) ( Figure S6A -C).
Manipulation of either CTCF or SMARCA5 Affects Transcriptional Outcome of the SPI1 Gene
Recruitment of CTCF and SMARCA5 onto the SPI1 gene in mixed myeloid cells as well as in AZA-treated OCI-M2 blasts indicated that CTCF and SMARCA5 might regulate the transcriptional outcome of SPI1. In order to address this possibility we decided to manipulate the levels of CTCF and SMARCA5 in human AML OCI-M2 blasts. Plasmid encoding the CTCF cDNA (pCTCF) or a SMARCA5 siRNA were transfected together with an additional plasmid encoding a green fluorescent protein (GFP) and immunoblots were performed on GFP positive cells. Perturbation experiments were done in OCI-M2 in absence of AZA as well as upon AZA that is known to stimulate expression PU.1 and its targets ( [15] and Figure S5 ). We expected two possibilities: 1) CTCF/SMARCA5 stimulate PU.1 expression by binding to newly demethylated DNA and facilitating PU.1 transcription, possibly through URE. Alternatively, 2) CTCF and SMARCA5 might employ the enhancer blocking function upon binding to the 214.4 Enhancer and thereby prevent transcription from the promoter and inhibit PU.1 levels. Our data support the second possibility as the manipulation of CTCF levels (by overexpression from the transiently transfected plasmid), either in the absence of AZA or upon preincubation with AZA, resulted in inhibition of PU.1 expression ( Figure 7A ). Furthermore, downregulation of SMARCA5 levels (by transient siRNA-mediated knockdown) in OCI-M2, both in the absence of AZA or upon preincubation with AZA, resulted in upregulation of PU.1 expression and thereby complemented the CTCF perturbation experiment ( Figure 7B ). Thus, both perturbation experiments in OCI-M2 AML blasts favor the possibility of enhancer-blocking effects of CTCF/SMARCA5 at the 214.4 Enhancer. To summarize this part, we have provided evidence of direct link between recruitment of CTCF/SMARCA5 at newly demethylated DNA at SPI1 regulatory regions and transcriptional outcome of SPI1 gene in AML blasts.
(OCI-M2 AZA) treatment. Y-axis: ChIP enrichment. X-axis: amplicons (distance relative to SPI1 TSS). URE, Upstream Regulatory Element of SPI1 gene; ENH, enhancer; ELE, element. Error bars: the standard errors (SE). Asterisks: p-values (t-test, 0.05-0.005). doi:10.1371/journal.pone.0087448.g004 
Discussion
Our work demonstrates an important role for a CTCF/ SMARCA5 interaction in the regulation of gene expression in AML by showing cooperating activities of CTCF and SMARCA5 on the SPI1 gene in AML blasts. First, we described the role of ATP-dependent chromatin remodeling factor Smarca5 during the process of Ctcf-ICR interaction. CTCF and SMARCA5 have been independently demonstrated to interact with cohesin [8] [18] . Cohesin and CTCF were found at the ICR where ChIP has demonstrated co-occupancy of CTCF and RAD21 and confirmed their cooperating effects on transcription [2] . So both the previous evidence together with our data suggest that SMARCA5 and Table S1 ) and control CD34+ cell donors (N = 1) and mixed myeloid cells (N = 1) was performed at the region 214.4 kb of SPI1 locus. The primer sequences are shown in Table S2 . C: % of DNA unmethylation, data in CD34+ cells of MDS patient without AZA therapy (N = 1) and MDS patient treated by AZA (N = 1). CTCF can interact on DNA in AML blasts also within the Cohesin complex. We show that Smarca5 is required for Ctcf association with chromatin at the ICR (Figure 1) . Interestingly, this is not mutual -Smarca5 associates with chromatin independently of Ctcf. Other work has shown that CTCF interacts with the chromatin remodeling enzyme CHD8 (Chromodomain, helicase, DNAbinding protein 8), however, it is not required for CTCF binding to the ICR. Instead, CHD8 is required for CTCF-mediated enhancer-blocking activity at ICR H19, similar to Smarca5 [17] .
What is the function of Ctcf/Smarca5 on DNA? The roles of both Ctcf and Smarca5 are complex as Ctcf and Smarca5 interact independently with other proteins. SMARCA5 interacts with protein complexes associated with nucleosome assembly and sliding: ACF [23] (with Acf1, a homologue of WCRF180), RSF [24] [25] [26] , WICH (with Wstf) [27] , NoRC [28] , and NURF [29] . These reports also indicate that the binding partner of Smarca5 in each chromatin remodeling complex dictates the functional outcome. For example, the NoRC [28] complex has a transcriptional repressive effect while NURF is involved in transcriptional activation [29] . Our data indicate that Ctcf directs the effects of Smarca5. At the ICR locus, the Ctcf and Smarca5 cooperate in transcriptional regulation and thus inhibition of either Ctcf or Smarca5 lead to similar transcriptional outcomes ( Figure 2 ). Upon perturbation experiments coupled by reporter assays (to determine enhancer-blocking effect) the Smarca5 knockdown appeared to be smaller compared to CTCF knockdown, however this can be attributed to higher stability of Smarca5 protein or differences in kinetics and level of knockdown. Nevertheless, Smarca5 with CTCF co-stimulates H19 expression and co-inhibits Igf2 expression ( Figure 3 ). This suggests that Smarca5 supports Ctcf function as an enhancer-blocking co-factor at the ICR.
Our work further demonstrates an important role for CTCF/ SMARCA5 in the regulation of SPI1 gene expression in AML. Levels of PU.1 dictate differentiation outcome [22] and if SPI1 transcription is downregulated by deletion of the URE it results in AML [13] . Our data show that CTCF, SMARCA5, and cohesin members are recruited to the SPI1 gene (Figures 4 & 5) during AZA-induced myeloid differentiation. The Cohesin complex partially overlaps with CTCF/SMARCA5 occupancy on DNA indicating it contributes to their function, possibly in a similar fashion as at the ICR [2] . In AML progenitors, the SPI1 gene is methylated and only SMARCA5 (without CTCF) can be detected at the URE while not at other regions. Upon DNA demethylation of AML blasts, the CTCF/SMARCA5 can newly interact with the 214.4 kb enhancer in the absence of cohesin (Figures 4 & 5) , CTCF/SMARCA5 occupancy with cohesin is also restored at the 211 kb element. At the URE, CTCF occupancy is not recruited upon AZA while SMARCA5 and cohesin are detectable equivalent to normal differentiating myeloid cells (Figures 4 & 5) . It remains not well understood how CTCF interaction with the 214.4 kb Enhancer upon AZA influences SPI1 gene transcription but we speculate that it may not be sufficient to facilitate interaction of the URE with the promoter and additional enhancers leading to its upregulation [14] . Instead it is likely that CTCF and SMARCA5 interact with the 214.4 Enhancer and block SPI1 transcription by employing the enhancer-blocking effects, similar to ICR. In addition, the DNA methylation pattern at the SPI1 gene in AML likely disables binding of CTCF to the URE and other regions, leading to disruption of a cascade of transcriptional mechanisms possibly also involving looping of the URE and maybe other elements (at 211 kb) with the promoter.
What may be the mechanism of enhancer-blocking at SPI1 gene used for? At the moment we do not have clear view but speculate that inhibition of PU.1 level is as important as its activation and may be used in blocking early differentiation decisions upon preceding DNA demethylation [30] . In addition, PU.1 silencing is of critical importance in erythroid lineage differentiation [31] . Alternatively, binding of CTCF/SMARCA5 at 214.4 Enhancer is aberrant and specific for AML undergoing DNA demethylation and may not exist in normal progenitor physiology. Nevertheless, while mechanisms of SPI1 gene activation were previously described [14] this is one of the first reports of its transcriptional repression.
We herein present a model that involves the DNA methylationsensing factor CTCF that cooperates on DNA with chromatin remodeling factor SMARCA5. At both studied DNA regions, ICR H19 and SPI1 gene regions, these factors co-occupy and coregulate these targets in a cooperative fashion. While DNA hypermethylation in AML prevents binding of CTCF (and its partners) leading to structural properties characterized by repression of the SPI1 gene, according to our ChIP data CTCF become recruited upon AZA in the 214.4 Enhancer while other regions were negative (Figure 4 ). This corresponds to DNA demethylation pattern of the 214.4 Enhancer ( Figure S6 ). In addition, we think that also Smarca5 plays crucial role, as chromatin remodeling factor, for Ctcf recruitment on DNA ( Figure 1C ). Furthermore, members of Cohesin complex colocalize with CTCF and SMARCA5 at the URE and also at the 211 kb Element and presumably influence SPI1 gene structure in differentiating myeloid cells. Demethylation therapy in AML is however not sufficient to restore SPI1 gene transcription to the level found in cells undergoing normal differentiation (Figure 8 ). Figure S4 Distribution of Ctcf and Smarca5 immunostaining in MEL cells (confocal laser scanning microscopy). MEL cells were fixed with 3,5% paraformaldehyde and immunostained with antibodies against Ctcf (green), Smarca5 (red), and DAPI (blue). Merge image as well as intensity profile graphs correspond to the section depicted by the line (see Merge). Fluorescence intensity profiles acquisition and determination of heterochromatin content was performed using ImageJ 1,38x software. Y-axis in intensity profile graphs represents fluorescence of respective fluorophor and X-axis represents distance. (EPS) Figure S5 mRNA expression of PU.1 and its target genes in OCI-M2 and normally differentiating mixed myeloid cells (heat map). mRNA from mixed myeloid cells, untreated OCI-M2 and OCI-M2 treated for 72 hrs with GCSF-AZA (see MM) were analyzed by RT-PCR. Y-axis: specific mRNA relative to average of HPRT1 and GAPDH was normalized to untreated OCI-M2. (EPS) Figure S6 A AZA-mediated DNA demethylation in untreated OCI-M2 and AZA-treated OCI-M2. Sequencing of bisulphitetreated DNA was performed over the regions 215.6 kb, 214.4 kb and 211.0 kb of SPI1 locus. The primer sequences are shown in Table S2 . Each region contains twelve CpGs as indicated below the graphs. B AZA-associated DNA demethylation was performed in CD34+ cells isolated from MDS patient without AZA therapy (N = 1, information in Table S1 ) and MDS patient after AZA therapy (N = 1). C DNA methylation of normal and AML/MDS CD34+ cells. The DNA was isolated from CD34+ cells of AML/ MDS patients (N = 3) and control donor (N = 1). Y-axis: % of unmethylated CpGs; x-axis: number of CpG. Arrows indicate demethylated CpGs. 
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Hematopoiesis in patients with mature B-cell malignancies is deregulated even in patients with undetectable bone marrow involvement
Mature B-cell malignancies represent the most common types of hematologic tumors. Despite this, little information is available on the composition and function of hematopoiesis in patients with these malignancies. Hematopoietic stem and progenitor cells (HSPCs) might be influenced by at least three key factors: 1. HSPCintrinsic mutations (that might predispose subjects to the development of these malignancies), 2. Direct or indirect impact of malignant lymphocytes present in the bone marrow (BM) or extramedullary tissue, and 3. Age-related changes. [1] [2] [3] [4] [5] The aim of the study herein was to analyze HSPC content in patients with thus far untreated mature B-cell malignancies.
We first confirmed the age-related changes observed by Kuranda et al. in our cohort of 22 control samples. 6 While the absolute numbers of hematopoietic stem cells (HSCs) did not change, we observed a negative correlation of their relative numbers with increasing age (Figure 1A ,C). The absolute, but not relative numbers of multipotent progenitors (MPPs) positively correlated with age ( Figure  1A ,C). The most statistically significant change was observed in the compartment of multilymphoid progeni-tors (MLPs), where both the absolute and relative frequencies positively correlated with age ( Figure 1A,C) . Both the absolute and relative numbers of pro-B cells were significantly lower in the control samples of the elderly ( Figure 1A,C) . In addition to the age-related changes, we have recently demonstrated that healthy Caucasians have significantly increased proportions of BM-derived pro-B cells compared to Asians. 7 To avoid any potential age-or race-related biases in HSPC frequencies, the control cohort used in this study comprised BM samples obtained from age-matched healthy Caucasians (all patients were Caucasians as well). The flow cytometry gating strategy is explained in detail in the Online Supplementary Materials and Methods.
All patient samples were obtained after written informed consent according to the Helsinki Declaration of 1975 (revised in 1985). The study was approved by the Ethics Committee of the Charles University General Hospital in Prague. The patient cohort (n=125, median age 65 years) included samples of chronic lymphocytic leukemia (CLL, n=21), diffuse large B-cell lymphoma (DLBCL, n=35), follicular lymphoma (FL, n=24), mantle cell lymphoma (MCL, n=27), and multiple myeloma (MM, n=18). Surprisingly, most of the age-related changes observed among control samples were not discernible in patient samples ( Figure 1B 
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B cells, which negatively correlated with increasing age (Figure 1B,D) . In contrast, the most statistically significant age-related change observed in controls, the increased absolute and relative numbers of MLP, was lost in patient samples ( Figure 1B,D) . The precise molecular mechanism underlying the observed loss of difference in the absolute and relative numbers of HSC, MPP, and especially MLP populations between the young and elderly patients remains elusive. The data, however, strongly suggests that hematopoiesis of the elderly, but not of the young, is impacted by the presence of malignant B cells, either in the BM, or in extramedullary locations (Figures 2A,B and 3D,E) . As a consequence the diseaserelated alterations of the hematopoiesis in the elderly might override the age-related changes normally observed in healthy individuals.
After the age-related analysis we analyzed HSPC changes in the whole patient cohort compared to agematched healthy controls. While absolute numbers of HSCs (from unselected bone marrow mononuclear cells (BMMCs)) were not changed, their relative numbers (from Lin -CD34 + CD38 -BMMC) were significantly increased (44.4 ± 16.8% versus 33.5 ± 14.9%, P=0.02) (Figure 2A,B) . While absolute numbers of MPP were significantly decreased (0.1896 ± 0.2061% versus 0.3495 ± 0.0808%, P=0.01, Figure 2A ), their relative numbers were not changed ( Figure 2B ). Both the absolute and relative numbers of MLP were significantly decreased in patients compared to controls: 0.04317 ± 0.05524% versus 0.1421 ± 0.1370% (P<0.0001), and 7.789 ± 6.584% versus 18.32 ± 11.38% (P<0.0001), respectively (Figure 2A,B) . The downregulation of MLP was also observed in the analyses of individual diagnoses, where all subtypes of mature B-cell malignances showed reduced absolute and relative MLP numbers ( Figure 2C,D) . Similarly, both absolute (from unselected BMMC) and relative (from CD34 + CD38 + BMMC) numbers of pro-B cells were not statistically different in patients compared to controls (Figure 2A,B) . The fact that HSPC deregulations were also observed in patient samples with undetectable BM infiltration strongly suggests that even extramedullary located lymphoma might impact normal hematopoiesis remotely. Precise molecular mediators that could remotely deregulate hematopoietic processes might include cytokines, growth factors, or other types of messengers (e.g., microRNA) produced by malignant lymphocytes and secreted into the plasmatic pool.
We © Ferrata Storti Foundation of trephine biopsy specimens with a range of between 2.5% and nearly 100% and a median of 40% ( Figure 3A) . Absolute numbers of all analyzed populations of HSPCs, with the exception of HSCs (i.e., MPP, MLP and pro-B), negatively correlated with the extent of BM involvement ( Figure 3B ). Plausibly, the data reflects a situation whereby malignant lymphocytes present in the BM oppress normal hematopoiesis. Not surprisingly, the most significant suppression of the absolute HSPC numbers was observed in CLL, which has the highest extent of BM involvement out of all of the analyzed B-cell malignancies ( Figure 2C,D) . While relative numbers of HSC and MLP demonstrated negative correlation with BM infiltration, relative numbers of MPP showed positive correlation with the extent of infiltration ( Figure 3C ). These data point to a more complex deregulation of hematopoiesis than mere spatial oppression of hematopoiesis by the presence of malignant B cells. There was no significant correlation between relative numbers of pro-B and BM infiltration ( Figure 3C ).
Hematopoiesis is a complex process orchestrated by dozens of hematopoietic transcription factors and other important genes. We asked whether the observed differences in the composition of HSPCs between patients and healthy controls would be associated with transcriptional deregulation of these important molecules. Gene expression analyses of 27 selected genes, including hematopoietic stem cell / B-cell / T-cell transcription factors, apoptosis-related genes, cell cycle regulators, stem cell markers and adhesion molecules, with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal control were carried out on sorted HSC samples obtained from haematologica 2017; 102:e154 
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